Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment

[Display omitted] CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves mult...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews Vol. 176; p. 113891
Main Authors: Xu, Xiaoyu, Liu, Chang, Wang, Yonghui, Koivisto, Oliver, Zhou, Junnian, Shu, Yilai, Zhang, Hongbo
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.09.2021
Subjects:
Animals
Cancer treatment
Clinic application
CRISPR-Cas Systems
CRISPR/Cas9
Delivery vectors
Gene Editing
Humans
Nanotechnology
Nanotechnology - methods
Neoplasms - genetics
Neoplasms - therapy
CRISPR/Cas9
Delivery vectors
Cancer treatment
Gene editing
Nanotechnology
Clinic application
ISSN:0169-409X, 1872-8294, 1872-8294
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract [Display omitted] CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
AbstractList CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
[Display omitted] CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
ArticleNumber 113891
Author Koivisto, Oliver
Wang, Yonghui
Zhou, Junnian
Shu, Yilai
Xu, Xiaoyu
Liu, Chang
Zhang, Hongbo
Author_xml – sequence: 1
  givenname: Xiaoyu
  surname: Xu
  fullname: Xu, Xiaoyu
  organization: ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200031, China
– sequence: 2
  givenname: Chang
  surname: Liu
  fullname: Liu, Chang
  organization: Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland
– sequence: 3
  givenname: Yonghui
  surname: Wang
  fullname: Wang, Yonghui
  organization: Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland
– sequence: 4
  givenname: Oliver
  surname: Koivisto
  fullname: Koivisto, Oliver
  organization: Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland
– sequence: 5
  givenname: Junnian
  surname: Zhou
  fullname: Zhou, Junnian
  organization: Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland
– sequence: 6
  givenname: Yilai
  surname: Shu
  fullname: Shu, Yilai
  organization: ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200031, China
– sequence: 7
  givenname: Hongbo
  surname: Zhang
  fullname: Zhang, Hongbo
  email: hongbo.zhang@abo.fi
  organization: Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34324887$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtLxDAURoMoOjP6B1xIl25a8-gjATcy-AJR8QHuQprcaoa2GZPMwPx7O9TZuHB1N-d8cM8U7feuB4ROCc4IJuXFIlPG-IxiSjJCGBdkD00Ir2jKqcj30WSARJpj8XGEpiEsMCa0KvEhOmI5oznn1QRdPareRdBfvWvd5yatVQCTGGjtGvwmcU0yf7l_fX65mKsgksb5RKteg0-iBxU76OMxOmhUG-Dk987Q-8312_wufXi6vZ9fPaSacULSUjBTm5zgSnOOC1LVOc95rWpuoOAMdKXqmrGGF1yxkhmsiGhESSgUrFSmYTN0Pu4uvfteQYiys0FD26oe3CpIWhQVpQLndEDPftFV3YGRS2875Tdy9_YA8BHQ3oXgoZHaRhWt66NXtpUEy21huZDbwnJbWI6FB5X-UXfr_0qXowRDoLUFL4O2MHQ01oOO0jj7n_4Dbq-SYA
CitedBy_id crossref_primary_10_1016_j_biopha_2025_118224
crossref_primary_10_1038_s41392_023_01309_7
crossref_primary_10_1088_1748_605X_ace39d
crossref_primary_10_3390_pharmaceutics16020213
crossref_primary_10_1016_j_biopha_2025_118589
crossref_primary_10_1016_j_envres_2023_116573
crossref_primary_10_1016_j_ajps_2025_101041
crossref_primary_10_1016_j_nxnano_2025_100149
crossref_primary_10_3390_molecules29092073
crossref_primary_10_1016_j_biomaterials_2023_122056
crossref_primary_10_1002_btm2_10474
crossref_primary_10_7759_cureus_50031
crossref_primary_10_1002_smll_202405593
crossref_primary_10_1002_wnan_1938
crossref_primary_10_1016_j_ijbiomac_2023_127060
crossref_primary_10_1016_j_ijbiomac_2025_142289
crossref_primary_10_1016_j_jare_2024_07_038
crossref_primary_10_1007_s10528_024_10799_1
crossref_primary_10_1002_adma_202300374
crossref_primary_10_2147_JHC_S456683
crossref_primary_10_1038_s41467_024_44941_9
crossref_primary_10_3389_fmolb_2025_1597144
crossref_primary_10_1016_j_chempr_2024_10_002
crossref_primary_10_1007_s12033_024_01124_7
crossref_primary_10_1016_j_actbio_2025_02_060
crossref_primary_10_1186_s12866_023_03136_w
crossref_primary_10_1007_s13346_023_01299_7
crossref_primary_10_1016_j_cej_2025_163429
crossref_primary_10_1016_j_nantod_2022_101532
crossref_primary_10_3390_cancers17061008
crossref_primary_10_1016_j_ejmech_2022_114801
crossref_primary_10_1002_mco2_693
crossref_primary_10_1186_s13287_024_03848_4
crossref_primary_10_1016_j_mcp_2024_102004
crossref_primary_10_1016_j_jddst_2023_105184
crossref_primary_10_1088_2632_959X_add7f5
crossref_primary_10_1002_adtp_202200287
crossref_primary_10_1002_adma_202300665
crossref_primary_10_3389_fnano_2022_931259
crossref_primary_10_1080_17435889_2025_2457781
crossref_primary_10_1016_j_ccr_2025_216897
crossref_primary_10_3389_fchem_2023_1259435
crossref_primary_10_3390_biomedicines11020453
crossref_primary_10_1002_adma_202312530
crossref_primary_10_3390_pharmaceutics14010041
crossref_primary_10_1002_jev2_70044
crossref_primary_10_3390_microorganisms13010172
crossref_primary_10_1002_sstr_202300086
crossref_primary_10_1080_09205063_2022_2121592
crossref_primary_10_1002_adma_202308029
crossref_primary_10_1016_j_cellsig_2023_110811
crossref_primary_10_1186_s12866_023_03058_7
crossref_primary_10_1016_j_aca_2022_339541
crossref_primary_10_1097_MS9_0000000000002821
crossref_primary_10_5312_wjo_v15_i10_932
crossref_primary_10_1016_j_heliyon_2024_e39323
crossref_primary_10_4291_wjgp_v16_i3_107834
crossref_primary_10_3389_fphar_2022_776895
crossref_primary_10_1007_s40097_022_00472_7
crossref_primary_10_3390_cells14151136
crossref_primary_10_1016_j_biomaterials_2025_123090
crossref_primary_10_1080_17425247_2023_2185220
crossref_primary_10_1186_s12985_025_02783_x
crossref_primary_10_3389_fgene_2024_1364742
crossref_primary_10_1016_j_cjac_2025_100590
crossref_primary_10_1186_s40164_023_00457_4
crossref_primary_10_1002_advs_202207512
crossref_primary_10_1016_j_ijpharm_2024_123845
crossref_primary_10_1016_j_mimet_2023_106876
crossref_primary_10_3390_pharmaceutics14091842
crossref_primary_10_1016_j_procbio_2023_03_020
crossref_primary_10_1016_j_medj_2022_12_001
crossref_primary_10_1016_j_apsb_2024_08_030
crossref_primary_10_1016_j_jconrel_2023_01_051
crossref_primary_10_1002_smmd_134
crossref_primary_10_1088_1361_6528_ac842d
crossref_primary_10_1016_j_matdes_2023_111931
crossref_primary_10_2147_IJN_S423737
crossref_primary_10_1088_1758_5090_add625
crossref_primary_10_3390_ijms24054778
crossref_primary_10_1002_adfm_202504296
crossref_primary_10_1016_j_tibtech_2023_06_005
crossref_primary_10_1016_j_ijbiomac_2025_147380
crossref_primary_10_3390_nano12081376
crossref_primary_10_1080_17410541_2024_2341610
crossref_primary_10_3389_fonc_2025_1499283
crossref_primary_10_1016_j_arr_2025_102851
crossref_primary_10_1016_j_heliyon_2023_e22095
crossref_primary_10_3390_biomedicines12081725
crossref_primary_10_1016_j_jddst_2023_104632
crossref_primary_10_1016_j_nantod_2022_101582
crossref_primary_10_3390_bioengineering9090477
crossref_primary_10_1177_09636897231219830
crossref_primary_10_1002_advs_202504220
crossref_primary_10_1016_j_ccr_2023_215634
crossref_primary_10_1016_j_indcrop_2024_119001
crossref_primary_10_1038_s41417_024_00761_z
crossref_primary_10_1016_j_jddst_2025_107455
crossref_primary_10_1016_j_jpha_2024_101119
crossref_primary_10_1016_j_sciaf_2023_e01700
crossref_primary_10_3389_fphar_2023_1271321
crossref_primary_10_1002_slct_202401823
crossref_primary_10_1002_wnan_1996
crossref_primary_10_3390_pharmaceutics16010062
crossref_primary_10_1016_j_nantod_2023_101913
crossref_primary_10_18287_2782_2966_2023_3_4_30_39
crossref_primary_10_1002_advs_202300195
crossref_primary_10_1002_jev2_70130
crossref_primary_10_1016_j_nantod_2022_101734
crossref_primary_10_1016_j_jddst_2024_105338
crossref_primary_10_61164_4watt240
crossref_primary_10_1016_j_cej_2024_152712
crossref_primary_10_1016_j_jconrel_2024_12_062
crossref_primary_10_1007_s10967_025_10233_9
crossref_primary_10_1016_j_apsb_2025_05_007
crossref_primary_10_3390_ijms24097786
crossref_primary_10_3390_ijms23031685
crossref_primary_10_3390_ijms232415758
crossref_primary_10_3390_bios13040450
crossref_primary_10_1016_j_jconrel_2023_08_028
crossref_primary_10_1186_s13046_025_03368_w
crossref_primary_10_1016_j_comptc_2025_115294
crossref_primary_10_3389_fonc_2023_1194350
crossref_primary_10_1016_j_bulcan_2025_03_007
crossref_primary_10_3389_fgeed_2022_1030285
crossref_primary_10_3390_ph17050612
crossref_primary_10_1038_s41417_024_00852_x
crossref_primary_10_3390_pharmaceutics15030984
crossref_primary_10_1186_s43094_024_00587_4
crossref_primary_10_1039_D3BM01629C
crossref_primary_10_1016_j_semcancer_2022_02_016
crossref_primary_10_1186_s12943_022_01518_8
crossref_primary_10_1186_s12951_024_02627_w
crossref_primary_10_1002_advs_202309314
crossref_primary_10_2147_IDR_S370869
crossref_primary_10_1016_j_jddst_2025_106798
crossref_primary_10_1186_s12951_022_01713_1
crossref_primary_10_1039_D2BM01636B
crossref_primary_10_2174_0115733947290474240315062214
crossref_primary_10_1002_SMMD_20230039
crossref_primary_10_1002_adfm_202301256
crossref_primary_10_1186_s12951_024_02486_5
crossref_primary_10_1002_mabi_202300577
crossref_primary_10_3390_ijms252413384
crossref_primary_10_1039_D3BM00788J
crossref_primary_10_3390_ma18112570
crossref_primary_10_1007_s10529_023_03454_z
crossref_primary_10_1007_s13346_023_01485_7
crossref_primary_10_1016_j_biomaterials_2023_122158
crossref_primary_10_1016_j_talanta_2025_128841
crossref_primary_10_1016_j_jddst_2025_107519
crossref_primary_10_1002_biot_202300352
crossref_primary_10_1002_adhm_202302615
crossref_primary_10_2174_0122106812372775250207074104
crossref_primary_10_1002_adma_202106945
crossref_primary_10_1016_j_jgar_2025_02_002
crossref_primary_10_1186_s40164_024_00570_y
Cites_doi 10.3389/fphar.2019.01456
10.1039/C4CS00229F
10.1016/j.jconrel.2013.04.018
10.1016/j.addr.2013.11.009
10.18632/oncotarget.16638
10.1038/s41388-020-01523-5
10.1007/s12272-020-01207-4
10.1073/pnas.1712963115
10.1089/nat.2018.0721
10.1016/j.addr.2012.09.036
10.1002/adma.201901081
10.7150/thno.42325
10.1186/s11671-018-2728-6
10.18632/oncotarget.16350
10.1073/pnas.1904697116
10.1002/anie.201905738
10.1126/science.2200121
10.1080/10717544.2020.1833382
10.1002/biot.202000150
10.3390/cancers10070238
10.1016/j.biopha.2016.12.041
10.1002/tcr.201700055
10.1007/s00604-018-2953-9
10.1002/adma.201902575
10.1208/s12248-018-0267-9
10.1007/s00432-020-03207-9
10.1038/nature08703
10.5625/lar.2018.34.4.257
10.1002/advs.201700175
10.1021/jacs.9b11638
10.1021/jacs.9b09043
10.1016/j.bbrc.2014.07.014
10.1371/journal.pone.0182373
10.1038/s41565-019-0539-2
10.2165/00003088-200342050-00002
10.1021/acs.accounts.9b00177
10.1159/000495714
10.1002/btm2.10152
10.1016/j.jconrel.2018.10.018
10.1002/smll.201301992
10.1021/acs.jnatprod.0c00642
10.1056/NEJMoa2107454
10.3390/ijms20194696
10.1016/j.drudis.2019.02.011
10.2174/1381612822666161025153619
10.1126/science.1225829
10.1002/ijc.32072
10.1016/j.lfs.2019.116636
10.1002/jps.20457
10.1002/advs.201802373
10.2174/1871520617666170419143459
10.1038/s41467-020-17962-3
10.1002/wnan.1609
10.1038/s41388-018-0292-2
10.1126/sciadv.abb4005
10.1021/acs.biomac.6b01704
10.1016/j.bbrc.2020.05.172
10.1002/med.21462
10.1016/j.jconrel.2009.09.023
10.1517/17425247.2012.673278
10.1016/j.lfs.2020.118525
10.1021/acsami.7b04038
10.1038/s41578-019-0145-9
10.3389/fphar.2017.00561
10.1002/adfm.201703036
10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3
10.1016/j.celrep.2020.108444
10.1016/j.canlet.2019.01.017
10.1128/JB.01415-07
10.2147/CMAR.S236374
10.1002/adma.201606134
10.1016/j.biomaterials.2011.02.022
10.1021/acsnano.6b04261
10.7150/thno.38069
10.2147/IJN.S168053
10.1126/science.aax0182
10.1021/jacs.9b03457
10.1038/s41568-020-0290-x
10.3109/10717544.2015.1055619
10.2174/1567201814666170516114411
10.1038/nbt.1602
10.1038/s41388-019-0887-2
10.1038/s41467-018-03705-y
10.1021/acs.nanolett.6b02536
10.1016/j.jconrel.2010.01.036
10.1021/acsnano.8b02053
10.2147/IJN.S147506
10.1038/s41374-018-0027-6
10.1186/s12885-019-5455-1
10.1002/jor.24227
10.3390/cancers9090116
10.1021/acsami.0c17660
10.1038/nature13420
10.1021/bm301718f
10.1186/s12929-020-00687-2
10.1126/science.1231143
10.1038/nrc3236
10.1093/jnci/djz196
10.1021/acsami.7b16764
10.1186/s13048-018-0406-z
10.1101/gr.171264.113
10.1039/C9BM02036E
10.1126/science.1232033
10.1021/acsami.9b23084
10.1016/S0021-9258(17)40292-4
10.1096/fj.201802213RR
10.1038/s41565-017-0012-z
10.1016/j.biotechadv.2019.02.006
10.1208/s12249-017-0740-2
10.1186/s13046-020-01603-0
10.1039/D0CC06241C
10.1016/j.actbio.2012.08.012
10.1021/acsnano.8b05151
10.1016/j.semcdb.2019.05.026
10.1016/j.jconrel.2020.03.015
10.1016/j.biomaterials.2017.09.015
10.1002/jgm.3107
10.1016/j.jconrel.2020.04.052
10.2217/nnm.15.183
10.1016/j.jconrel.2006.06.024
10.1002/anie.201708689
10.1002/smll.201403073
10.1016/j.jconrel.2020.12.027
10.1021/acsnano.9b05276
10.1007/s00239-004-0046-3
10.1038/s41573-020-0089-1
10.1039/D0NR05452F
10.1016/j.biomaterials.2020.120275
10.1002/ctm2.34
10.1039/C6BM00189K
10.2147/DDDT.S165440
10.2147/IJN.S198848
10.3390/cancers11101490
10.1038/nbt.3081
10.1002/wnan.1339
10.1016/j.jconrel.2019.05.019
10.1016/j.nano.2014.09.014
10.1016/j.addr.2015.09.012
10.1016/j.apsb.2019.07.004
10.1002/anie.201802701
10.1371/journal.pone.0204976
10.1089/hum.2019.312
10.1126/sciadv.aav7199
10.1126/sciadv.aaw8922
10.1021/nn102711d
10.1038/s41588-019-0554-0
10.1080/1061186X.2018.1455841
10.1016/j.biomaterials.2019.119619
10.1186/s11671-020-03334-9
10.1038/s41467-020-17029-3
10.1073/pnas.1912220117
10.1021/nn204102q
10.1016/j.ccr.2009.10.013
10.1016/j.yexcr.2020.112040
10.1128/jb.169.12.5429-5433.1987
10.1002/bip.10257
10.1021/acsami.8b17481
10.1016/j.biopha.2018.12.048
10.3389/fphar.2015.00286
10.1073/pnas.1821893117
10.1016/j.biopha.2018.04.055
10.1016/j.jconrel.2020.02.045
10.1002/ddr.21545
10.1089/hum.2017.209
10.1038/s41419-019-2093-0
10.1021/bm101080p
10.1038/s41573-018-0006-z
10.1021/acs.bioconjchem.9b00669
10.1002/anie.201806941
10.1038/sj.onc.1206866
10.1046/j.1365-2958.2002.02839.x
10.7150/thno.13532
10.1111/php.13305
10.1016/j.yexcr.2018.08.009
10.1016/j.jconrel.2020.02.019
10.1073/pnas.84.21.7413
10.1128/JB.01412-07
10.1016/j.addr.2016.02.006
10.1007/s13346-020-00816-2
10.1021/jacs.7b11754
10.1002/advs.201903381
10.2174/0929867325666180111095913
10.7554/eLife.04766
10.1002/advs.201700540
10.1126/science.aae0477
10.1126/sciadv.abc9450
10.1002/anie.201403036
10.1007/s12274-020-3066-4
10.3390/pharmaceutics12111001
10.1016/j.ymthe.2018.07.019
10.1002/smll.201803061
10.1590/0001-3765201820170387
10.1039/C9SC06497D
10.4103/1735-5362.235156
10.1002/tcr.201700033
10.1016/j.biomaterials.2018.04.031
10.1038/am.2017.185
10.1016/j.addr.2019.11.005
10.2217/nnm.14.178
10.1080/17425247.2019.1604680
10.1016/j.ymthe.2019.08.012
10.1016/j.jconrel.2014.04.015
10.1093/nar/gkaa683
10.1007/s13346-020-00789-2
10.1016/j.biomaterials.2014.02.031
10.1021/acsnano.5b00929
10.1021/nn3046055
10.1039/C9CS00575G
10.1038/s41563-021-01047-7
10.1002/adma.202000208
10.3109/10717544.2013.838077
10.1158/1078-0432.CCR-19-1351
10.1088/0957-4484/27/18/185704
10.1038/s41563-020-0669-9
10.1002/adma.201900795
10.18632/oncotarget.21863
10.1016/j.jconrel.2020.07.033
10.1038/s41568-019-0179-8
10.3389/fonc.2020.01529
10.1021/acsbiomaterials.0c00516
10.1016/j.jconrel.2017.09.013
10.1016/j.synbio.2018.10.003
10.1080/10408398.2016.1231168
10.1021/acs.biomac.8b00422
10.1007/s40820-020-00423-3
10.1016/j.biomaterials.2020.119791
10.18632/oncotarget.26677
10.1002/advs.202002788
10.1021/acsami.9b17749
10.1016/j.cell.2020.02.001
10.1007/s11095-015-1784-1
10.1073/pnas.1121174109
10.3389/fimmu.2020.02062
10.1021/nn102357y
10.1016/j.stem.2020.04.003
10.1126/science.341.6148.833
10.2147/IJN.S165210
10.2174/1568026619666190125161517
10.1111/cpr.12965
10.18632/oncotarget.14072
10.1128/MMBR.67.4.657-685.2003
10.3389/fonc.2018.00653
10.1016/j.semcancer.2018.04.001
10.1021/acsami.9b12335
10.1007/s10103-017-2317-4
10.1038/natrevmats.2016.14
10.1002/anie.201506030
10.1016/j.addr.2018.08.005
10.1038/s41388-020-01570-y
10.1002/ijc.33252
10.18632/aging.102515
10.18632/oncotarget.13148
10.1038/s41586-019-1103-9
10.1126/science.1138140
10.1021/jacs.8b01551
10.1007/s12274-019-2465-x
10.1039/b907978e
10.1111/pcmr.12825
10.1016/j.nantod.2016.04.008
10.1021/acsnano.9b10219
10.1021/acsami.6b04933
10.1016/j.jconrel.2017.09.012
10.1099/mic.0.28048-0
10.1002/pola.21996
10.1038/s41571-019-0316-z
10.2217/nnm.13.223
10.1016/j.canlet.2019.01.045
10.1038/nnano.2014.208
ContentType Journal Article
Copyright 2021 The Author(s)
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2021 The Author(s)
– notice: Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.addr.2021.113891
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1872-8294
ExternalDocumentID 34324887
10_1016_j_addr_2021_113891
S0169409X21002830
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
23M
4.4
457
4G.
53G
5GY
5VS
6I.
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAFTH
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATCM
AAXUO
ABFNM
ABGSF
ABJNI
ABMAC
ABUDA
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CS3
DOVZS
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HX~
HZ~
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSP
SSU
SSZ
T5K
TEORI
WUQ
Y6R
~G-
9DU
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACLOT
ACRPL
ACVFH
ADCNI
ADNMO
ADVLN
AEIPS
AEUPX
AFJKZ
AFPUW
AGQPQ
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
EFKBS
~HD
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3811-693dbd4107c880517b4848bab8de583ec7abb33f858a363d0a19f9612e536adf3
ISSN 0169-409X
1872-8294
IngestDate Sun Sep 28 14:11:00 EDT 2025
Wed Feb 19 02:27:57 EST 2025
Sat Nov 29 07:21:56 EST 2025
Tue Nov 18 20:40:15 EST 2025
Fri Feb 23 02:38:30 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords CRISPR/Cas9
Delivery vectors
Cancer treatment
Gene editing
Nanotechnology
Clinic application
Language English
License This is an open access article under the CC BY license.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3811-693dbd4107c880517b4848bab8de583ec7abb33f858a363d0a19f9612e536adf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://dx.doi.org/10.1016/j.addr.2021.113891
PMID 34324887
PQID 2557229042
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2557229042
pubmed_primary_34324887
crossref_citationtrail_10_1016_j_addr_2021_113891
crossref_primary_10_1016_j_addr_2021_113891
elsevier_sciencedirect_doi_10_1016_j_addr_2021_113891
PublicationCentury 2000
PublicationDate September 2021
2021-09-00
20210901
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: September 2021
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Advanced drug delivery reviews
PublicationTitleAlternate Adv Drug Deliv Rev
PublicationYear 2021
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Rizk, Christoforou, Lee (b0775) 2016; 27
Rouet, Thuma, Roy, Lintner, Rubitski, Finley, Wisniewska, Mendonsa, Hirsh, de Onate, Barron, McLellan, Bellenger, Feng, Varghese, Chrunyk, Borzilleri, Hesp, Zhou, Ma, Tu, Dullea, McClure, Wilson, Liras, Mascitti, Doudna (b1275) 2018; 140
Guo, Yang, Huang, Auguste, Moses (b1340) 2019; 116
Mi (b1380) 2020; 10
Genovese, Schiroli, Escobar, Di Tomaso, Firrito, Calabria, Moi, Mazzieri, Bonini, Holmes, Gregory, van der Burg, Gentner, Montini, Lombardo, Naldini (b0150) 2014; 510
Ashley, Carnes, Epler, Padilla, Phillips, Castillo, Wilkinson, Wilkinson, Burgard, Kalinich, Townson, Chackerian, Willman, Peabody, Wharton, Brinker (b0715) 2012; 6
Bouche, Hsu, Dong, Kim, Taing, Cormode (b0770) 2020; 31
Liu, Ran, Chen, Kuang, Tang, Mei, Zhang, Gao, Zhang, He (b1200) 2014; 35
Deng, Tan, Gao, Zou, Xu, Tu, Song, Fan, Huang, Zhang (b1480) 2020; 10
Hanafy, El-Kemary, Leporatti (b0520) 2018; 10
Li, Hu, Chen (b0800) 2018; 171
Abuchowski, Mccoy, Palczuk, Vanes, Davis (b0915) 1977; 252
Sun, Ji, Hall, Hu, Wang, Beisel, Gu (b0900) 2015; 54
Mali, Yang, Esvelt, Aach, Guell, DiCarlo, Norville, Church (b0040) 2013; 339
Battaglia, Gallarate (b0600) 2012; 9
Li, Xiao, Yong, Li, Gan, Yang (b0910) 2020; 49
Wu, Yang (b0510) 2017; 29
Zuris, Thompson, Shu, Guilinger, Bessen, Hu, Maeder, Joung, Chen, Liu (b0640) 2015; 33
Aleksandrowicz, Taciak, Krol (b0490) 2017; 68
Probst, Zrazhevskiy, Bagalkot, Gao (b0790) 2013; 65
Bertrand, Wu, Xu, Kamaly, Farokhzad (b1000) 2014; 66
Martinez-Jimenez, Muinos, Sentis, Deu-Pons, Reyes-Salazar, Arnedo-Pac, Mularoni, Pich, Bonet, Kranas, Gonzalez-Perez, Lopez-Bigas (b0175) 2020; 20
Ramakrishna, Dad, Beloor, Gopalappa, Lee, Kim (b0840) 2014; 24
Shi, van der Meel, Theek, Blenke, Pieters, Fens, Ehling, Schiffelers, Storm, van Nostrum, Lammers, Hennink (b0530) 2015; 9
Liu, Yin, Xu, Zhang, Shi, Cao (b0725) 2019; 6
Tong, Moyo, Lee, Leong, Bao (b0070) 2019; 4
Grant, Cai, Risinger, Liang, O'Keefe, Doench, Cichewicz, Mooberry (b0270) 2020; 83
Parfejevs, Sagini, Buss, Sobolevska, Llorente, Riekstina, Abols (b1050) 2020; 9
Mashreghi, Zamani, Moosavian, Jaafari (b1110) 2020; 15
Parra-Nieto, del Cid, de Carcer, Baeza (b0080) 2021; 16
Marraffini, Sontheimer (b0120) 2010; 463
Liu, Mei, Xu, Yu, Shi, Zhang, Wang, Zhang, Gao, Zhang, He (b1205) 2016; 6
Prolo, Li, Owen, Parker, Foshay, Nitta, Morgens, Bolin, Wilson, Vega, Luo, Nwagbo, Waziri, Li, Reimer, Bassik, Grant (b0385) 2019; 9
Zhang, Pei, Shi, Guo, Cui, Li, Zhang, Hu (b0400) 2019; 111
Xu, Wan, Xin, Li, Pan, Wu, Ping (b0065) 2019; 21
Deng, Hou, Li, Li, Zhang, Deng, Cheng, Lin (b0740) 2015; 5
Mintz, Lao, Chi, He, Li, Quek, Shao, Chen, Han, Wang, Leong (b0275) 2020; 5
Carvalho, Paiva, Campello, Paulo, Mergny, Salgado, Queiroz, Cruz (b1090) 2019; 9
Asadujjaman, Cho, Jang, Kim, Jee (b1465) 2020; 43
Li, Liu, Fontana, Ding, Liu, Hirvonen, Santos (b0685) 2018; 30
Gao, Jin, Tan, Zhang, Zou, Zhang, Ding, Das, Severinov, Hitzeroth, Debata, He, Ma, Tian, Gao, Wu, Tian, Cui, Fan, Huang, Cao, Bao, Tan, Hu (b0885) 2020; 321
Liu, Chang, Jiang, Meng, Sun, Mao, Xu, Wang (b1385) 2019; 31
Sahay, Alakhova, Kabanov (b1325) 2010; 145
Gabizon, Shmeeda, Barenholz (b0935) 2003; 42
Gao, Ouyang, Kang, Han, Xiong, Ding, Li, Wang, Huang, Chen, Wang, Dong, Zhang, Li, Ze, Hou, Yang, Ma, Gu, Chao (b0215) 2020; 10
Gillmore, Gane, Tauel, Kao, Fontana, Maitland, Seitzer, O’Connell, Walsh, Wood, Phillips, Xu, Amaral, Boyd, Cehelsky, Mckee, Schiermeier, Harari, Chir, Murphy, Kyratsous, Zambrowicz, Soltys, Gutstein, Leonard, Sepp-Lorenzino, Lebwohl (b0480) 2021
Basha (b0505) 2018; 15
Xue, Zhong, Sun, Sun, Hu, Pan (b0390) 2019; 10
Gothwal, Khan, Gupta (b0525) 2016; 33
Liu, He, Zhuo, Cheng (b1095) 2018; 291
Bockamp, Rosigkeit, Siegl, Schuppan (b1460) 2020; 9
Taratula, Kuzmov, Shah, Garbuzenko, Minko (b0620) 2013; 171
Ercolano, De Cicco, Rubino, Terrazzano, Ruggiero, Carriero, Kunderfranco, Ianaro (b0350) 2019; 10
Zhan, Rindtorff, Betge, Ebert, Boutros (b0045) 2019; 55
Jinek, Chylinski, Fonfara, Hauer, Doudna, Charpentier (b0135) 2012; 337
Xu, Zhang, Zhao, Qin, Cai, Geng, Zhu, Zhang, Zhang, Tan, Wang, Zhou (b1065) 2020; 326
Xu, Chhangawala, Cocco, Razavi, Cai, Otto, Ferrando, Selenica, Ladewig, Chan, Paula, Witkin, Cheng, Park, Serna-Tamayo, Zhao, Wu, Sallaku, Qu, Zhao, Collings, D'Avino, Jhaveri, Koche, Levine, Reis-Filho, Kadoch, Scaltriti, Leslie, Baselga, Toska (b0190) 2020; 52
Trac, Chung (b1180) 2020; 5
Kijanka, Dorresteijn, Oliveira, Henegouwen (b1035) 2015; 10
Wei, Cheng, Min, Olson, Siegwart (b0975) 2020; 11
Xu, Chen, Luo, Zhang, Zhao, Lu, Czarna, Gu, Wang (b0805) 2021; 168
Tang, Yu, Gao, Cong, Song, Lu (b1345) 2018; 25
Dorand, Nthale, Myers, Barkauskas, Avril, Chirieleison, Pareek, Abbott, Stearns, Letterio, Huang, Petrosiute (b1485) 2016; 353
Zhu, Chen (b1070) 2018; 134
Bolotin, Ouinquis, Sorokin, Ehrlich (b0100) 2005; 151
Liu, Zhao, Zhang, Xu, Xu, Li, Min, Shi, Zhao, Wei, Wang, Nie (b1350) 2019; 31
Tang, Liu, Jiang, Zhang, Mao, Wang (b1390) 2019; 11
Zhou, Mudianto, Ma, Riley, Uppaluri (b0195) 2020; 26
Riley, June, Langer, Mitchell (b1455) 2019; 18
Tu, Deng, Kong, Wang, Yang, Hu, Hu, Yang, Zhang (b1490) 2020; 12
Poddar, Pyreddy, Carraro, Dhakal, Rassell, Field, Reddy, Falcaro, Doherty, Shukla (b1265) 2020; 56
Cimadamore, Cheng, Santoni, Lopez-Beltran, Battelli, Massari, Galosi, Scarpelli, Montironi (b1115) 2018; 8
Mi, Liu, Feng (b0535) 2011; 32
Chen, Li, Zhao, Wu, Zhu, Mao, Gao (b0755) 2018; 3
Zhang, Luo, Zou, Wu, Jiang, Le, Zhao, Chen, Shao (b0290) 2020; 12
Wasungu, Hoekstra (b1320) 2006; 116
Yin, Yuan, Luo, Lu, Qin, Zhang, Shi, Zhu, Yang, Li, Jiang, Luo, Shan, Chen, You (b1335) 2020; 7
Es, Gavahian, Marti-Quijal, Lorenzo, Khaneghah, Tsatsanis, Kampranis, Barba (b0160) 2019; 37
Aaghaz, Gohel, Kamal (b0495) 2019; 19
Araste, Aliabadi, Abnous, Taghdisi, Ramezani, Alibolandi (b0555) 2021; 330
Ash, Dubec, Donne, Bashford (b1425) 2017; 32
He, Ali, Xu, Kumaravel, Si, Li, Sun, Ma, Xiao (b1055) 2020; 392
Moore, Rosenberg, McCormick, Malek (b0210) 2020; 19
Scott, Wolchok, Old (b1020) 2012; 12
Azangou-Khyavy, Ghasemi, Khanali, Boroomand-Saboor, Jamalkhah, Soleimani, Kiani (b0180) 2020; 11
Gupta, Bhattacharjee, Mandal, Sen, Dey, Dasgupta, Kazi, Gupta, Sinharoy, Acharya, Chattopadhyay, Ravichandiran, Roy, Ghosh (b0155) 2019; 232
Castro, Forero-Doria, Guzman (b0545) 2018; 90
Wang, Zhang, Hao, Li, Li, Wang (b0615) 2016; 23
Cai, Xu, Shuai, Zhu, Xu, Gao, Sun (b1175) 2020; 8
Topalian, Taube, Pardoll (b0470) 2020; 367
Liang, Li, Wang, Zhang, Wang, He, Li, Chen, Shaikh, Liu, Wu, Peng, Dang, Guo, He, Au, Lu, Zhu, Zhang, Lu, Zhang (b1135) 2017; 147
Wang, Shahi, Xie, Zhang, Abdeen, Yodsanit, Ma, Saha, Pattnaik, Gong (b1370) 2020; 324
Lu, Xue, Deng, Zhou, Yu, Deng, Huang, Yi, Liang, Wang, Shen, Tong, Wang, Li, Song, Li, Su, Ding, Gong, Zhu, Wang, Zou, Zhang, Li, Zhou, Liu, Yu, Wang, Zhang, Yin, Xia, Zeng, Zhou, Ying, Chen, Wei, Li, Mok (b0185) 2020; 26
Wan, Chen, Pan, Xu, Kang, Gao, Huang, Wu, Ping (b0850) 2020; 322
Zhou, Cui, Ying, Yu (b0890) 2018; 57
Gan, Li, Sui, Corke (b1245) 2018; 58
Iturrioz-Rodriguez, Correa-Duarte, Fanarraga (b0700) 2019; 14
Wang, Zhang, Xie, Wang, Tang, Zheng, Jiang (b0895) 2017; 4
Chen, Chen, Xin, Wan, Ping (b1450) 2020; 117
Zhang, Kuang, He, Liu, Lu, Li, Zhou, Huang (b1415) 2021; 14
Cong, Ran, Cox, Lin, Barretto, Habib, Hsu, Wu, Jiang, Marraffini, Zhang (b0035) 2013; 339
Kavand, Anton, Vandamme, Serra, Chan-Seng (b0875) 2020; 321
de Lazaro, Mooney (b0810) 2021
Yang, Chen, Yang, Wu, Liu, Li, Liu, Chen, Qiu (b0945) 2017; 9
Degors, Wang, Rehman, Zuhorn (b1270) 2019; 52
Moghassemi, Hadjizadeh (b0645) 2014; 185
Bakke, Wright, Zamora, Oladimeji, Crawford, Brewer, Autry, Evans, Thomas, Chen (b0420) 2019; 19
Wang, Li, Liu, Chen, Li (b0610) 2017; 86
Wilhelm, Tavares, Dai, Ohta, Audet, Dvorak, Chan (b0995) 2016; 1
Zheng, Li, Wang (b0050) 2020; 10
Hilgenbrink, Low (b1230) 2005; 94
Wang, Zuo, Du, Wang, Sun, Cao, Ye, Wang, Leong, Wang (b0835) 2016; 11
Jansen, van Embden, Gaastra, Schouls (b0090) 2002; 43
Sun, He, Yang, Hu, Cheng, Xiao, Yang, Wen, Zhou, Xie, Shen, Wu, Zheng (b0295) 2018; 98
Tuerk, Gold (b1075) 1990; 249
Pan, Yang, Luan, Liu, Li, Yang, Huang, Sun, Wang, Lin, Song (b1430) 2019; 5
Zhang, Mou, Jiang (b0760) 2020; 11
Hazafa, Mumtaz, Farooq, Bilal, Chaudhry, Firdous, Naeem, Ullah, Yameen, Mukhtiar, Zafar (b0130) 2020; 263
Mojica, Diez-Villasenor, Garcia-Martinez, Soria (b0095) 2005; 60
Seleci, Maurer, Stahl, Scheper, Garnweitner (b0655) 2019; 20
Watanabe, Shimada, Akiyama, Ishikawa, Ogura, Ogawa, Ono, Mitsunori, Ban, Kudo, Yamaoka, Tanabe, Tanaka (b0425) 2019; 145
Wu, Xu (b0575) 2018; 3
Rosenblum, Gutkin, Kedmi, Ramishetti, Veiga, Jacobi, Schubert, Friedmann-Morvinski, Cohen, Behlke, Lieberman, Peer (b0845) 2020; 6
Xiao, Wan, Nur, Dou, Mankin, Liu, Ouyang (b0430) 2018; 51
Semple, Akinc, Chen, Sandhu, Mui, Cho, Sah, Stebbing, Crosley, Yaworski, Hafez, Dorkin, Qin, Lam, Rajeev, Wong, Jeffs, Nechev, Eisenhardt, Jayaraman, Kazem, Maier, Srinivasulu, Weinstein, Chen, Alvarez, Barros, De, Klimuk, Borland, Kosovrasti, Cantley, Tam, Manoharan, Ciufolini, Tracy, de Fougerolles, MacLachlan, Cullis, Madden, Hope (b1310) 2010; 28
Liu, Wang, Zheng, Zhao, Wang, Hao, Zhao, Yi, Shi, Kang, Liu (b1475) 2020; 258
Zhou, Li, Jing, Zuo, Zheng (b0285) 2020; 146
Ouyang, Liu, Tan, Li, Yang, Zeng, Huang, Kong, Liu, Zhou, Liu (b0330) 2019; 9
Lin, Staahl, Alla, Doudna (b0145) 2014; 3
Sayed, Haj-Ahmad, Ruparelia, Arshad, Chang, Ahmad (b0665) 2017; 18
Liu, Wang, Luo (b0125) 2018; 3
Piffoux, Silva, Wilhelm, Gazeau, Tareste (b1145) 2018; 12
Ng, Rideout, Akama-Garren, Bhutkar, Mercer, Schenkel, Bronson, Jacks (b0230) 2020; 117
Kulkarni, Cullis, van der Meel (b1315) 2018; 28
Ghasemiyeh, Mohammadi-Samani (b0595) 2018; 13
Slotta, Schluter, Ruiz-Perera, Kadhim, Tertel, Henkel, Hubner, Greiner, Huser, Kaltschmidt, Kaltschmidt (b0460) 2017; 12
Horvath, Romero, Coute-Monvoisin, Richards, Deveau, Moineau, Boyaval, Fremaux, Barrangou (b0110) 2008; 190
Wang, Zhao, Han, Bai, Li, Liu, Che, Hu, Zhang, Jiang, Wang (b0695) 2015; 11
Chen, Mao, Xu, Weng, Mao, Ji (b0030) 2019; 447
Narmani, Rezvani, Farhood, Darkhor, Mohammadnejad, Amini, Refahi, Goushbol
Carlisle (10.1016/j.addr.2021.113891_b0265) 2020; 10
Kijanka (10.1016/j.addr.2021.113891_b1035) 2015; 10
Zhao (10.1016/j.addr.2021.113891_b1010) 2020; 181
Parfejevs (10.1016/j.addr.2021.113891_b1050) 2020; 9
Fu (10.1016/j.addr.2021.113891_b1190) 2019; 27
Zhu (10.1016/j.addr.2021.113891_b0345) 2020; 10
Kramer (10.1016/j.addr.2021.113891_b0880) 2007; 45
Sun (10.1016/j.addr.2021.113891_b1150) 2015; 11
Li (10.1016/j.addr.2021.113891_b0415) 2019; 304
Kavand (10.1016/j.addr.2021.113891_b0875) 2020; 321
Sun (10.1016/j.addr.2021.113891_b1220) 2014; 53
Cong (10.1016/j.addr.2021.113891_b0035) 2013; 339
Landgraf (10.1016/j.addr.2021.113891_b0675) 2020; 240
Narmani (10.1016/j.addr.2021.113891_b1225) 2019; 80
Deng (10.1016/j.addr.2021.113891_b0740) 2015; 5
Wang (10.1016/j.addr.2021.113891_b0615) 2016; 23
Barrangou (10.1016/j.addr.2021.113891_b0105) 2007; 315
Post (10.1016/j.addr.2021.113891_b0305) 2019; 10
Chen (10.1016/j.addr.2021.113891_b0405) 2020; 12
Mendes (10.1016/j.addr.2021.113891_b0500) 2017; 22
Prolo (10.1016/j.addr.2021.113891_b0385) 2019; 9
Tang (10.1016/j.addr.2021.113891_b0440) 2019; 37
Scott (10.1016/j.addr.2021.113891_b1020) 2012; 12
Gan (10.1016/j.addr.2021.113891_b1245) 2018; 58
Bockamp (10.1016/j.addr.2021.113891_b1460) 2020; 9
Wohlhieter (10.1016/j.addr.2021.113891_b0250) 2020; 33
Han (10.1016/j.addr.2021.113891_b0820) 2014; 10
Yang (10.1016/j.addr.2021.113891_b0945) 2017; 9
Battaglia (10.1016/j.addr.2021.113891_b0600) 2012; 9
Ghasemiyeh (10.1016/j.addr.2021.113891_b0595) 2018; 13
Singh (10.1016/j.addr.2021.113891_b1125) 2020; 9
Zheng (10.1016/j.addr.2021.113891_b0050) 2020; 10
Dorand (10.1016/j.addr.2021.113891_b1485) 2016; 353
Xiao (10.1016/j.addr.2021.113891_b0680) 2020; 27
Yan (10.1016/j.addr.2021.113891_b0785) 2018; 185
Deng (10.1016/j.addr.2021.113891_b0075) 2019; 12
Zhen (10.1016/j.addr.2021.113891_b1355) 2020; 31
Chen (10.1016/j.addr.2021.113891_b0565) 2010; 142
Felgner (10.1016/j.addr.2021.113891_b0635) 1987; 84
Gao (10.1016/j.addr.2021.113891_b0215) 2020; 10
Hu (10.1016/j.addr.2021.113891_b0570) 2017; 18
Liu (10.1016/j.addr.2021.113891_b1350) 2019; 31
Liu (10.1016/j.addr.2021.113891_b0745) 2020; 7
Rehman (10.1016/j.addr.2021.113891_b0605) 2017; 12
Mali (10.1016/j.addr.2021.113891_b0040) 2013; 339
Wang (10.1016/j.addr.2021.113891_b0730) 2020; 230
Liu (10.1016/j.addr.2021.113891_b0725) 2019; 6
Zhang (10.1016/j.addr.2021.113891_b0400) 2019; 111
Liu (10.1016/j.addr.2021.113891_b1385) 2019; 31
Tu (10.1016/j.addr.2021.113891_b1490) 2020; 12
Gonzalez-Salinas (10.1016/j.addr.2021.113891_b0280) 2020; 529
Ye (10.1016/j.addr.2021.113891_b0870) 2011; 12
Kim (10.1016/j.addr.2021.113891_b0410) 2018; 34
Raoof (10.1016/j.addr.2021.113891_b0235) 2019; 38
Asadujjaman (10.1016/j.addr.2021.113891_b1465) 2020; 43
Wang (10.1016/j.addr.2021.113891_b0695) 2015; 11
Liu (10.1016/j.addr.2021.113891_b1475) 2020; 258
Santos (10.1016/j.addr.2021.113891_b0670) 2014; 9
Nabavinia (10.1016/j.addr.2021.113891_b1080) 2017; 37
Sun (10.1016/j.addr.2021.113891_b0735) 2020; 12
Horvath (10.1016/j.addr.2021.113891_b0110) 2008; 190
Mengoni (10.1016/j.addr.2021.113891_b0370) 2020; 147
Kim (10.1016/j.addr.2021.113891_b0475) 2011; 5
Wei (10.1016/j.addr.2021.113891_b0975) 2020; 11
Hilgenbrink (10.1016/j.addr.2021.113891_b1230) 2005; 94
Abdelkader (10.1016/j.addr.2021.113891_b0650) 2014; 21
Lin (10.1016/j.addr.2021.113891_b1400) 2019; 141
Wang (10.1016/j.addr.2021.113891_b1330) 2018; 115
Sahay (10.1016/j.addr.2021.113891_b1325) 2010; 145
Mirza (10.1016/j.addr.2021.113891_b0015) 2019; 96
Cai (10.1016/j.addr.2021.113891_b1175) 2020; 8
Semple (10.1016/j.addr.2021.113891_b1310) 2010; 28
Watanabe (10.1016/j.addr.2021.113891_b0425) 2019; 145
Wu (10.1016/j.addr.2021.113891_b0575) 2018; 3
Ash (10.1016/j.addr.2021.113891_b1425) 2017; 32
Liu (10.1016/j.addr.2021.113891_b1095) 2018; 291
Araste (10.1016/j.addr.2021.113891_b0555) 2021; 330
Hussmann (10.1016/j.addr.2021.113891_b0240) 2017; 8
Khosa (10.1016/j.addr.2021.113891_b0590) 2018; 103
Yin (10.1016/j.addr.2021.113891_b1335) 2020; 7
Wang (10.1016/j.addr.2021.113891_b0895) 2017; 4
Kalaydina (10.1016/j.addr.2021.113891_b0485) 2018; 13
Liu (10.1016/j.addr.2021.113891_b0905) 2019; 5
Liu (10.1016/j.addr.2021.113891_b0060) 2017; 266
Jansen (10.1016/j.addr.2021.113891_b0090) 2002; 43
Iams (10.1016/j.addr.2021.113891_b0220) 2020; 17
Xue (10.1016/j.addr.2021.113891_b0390) 2019; 10
Guan (10.1016/j.addr.2021.113891_b0970) 2016; 16
Pennisi (10.1016/j.addr.2021.113891_b0025) 2013; 341
Nieberler (10.1016/j.addr.2021.113891_b1185) 2017; 9
Jinek (10.1016/j.addr.2021.113891_b0135) 2012; 337
Roidos (10.1016/j.addr.2021.113891_b0140) 2020; 11
Ng (10.1016/j.addr.2021.113891_b0230) 2020; 117
Carvalho (10.1016/j.addr.2021.113891_b1090) 2019; 9
Tsai (10.1016/j.addr.2021.113891_b1255) 2016; 11
Zhen (10.1016/j.addr.2021.113891_b0450) 2014; 450
Tuerk (10.1016/j.addr.2021.113891_b1075) 1990; 249
Sun (10.1016/j.addr.2021.113891_b0550) 2016; 4
Deng (10.1016/j.addr.2021.113891_b1480) 2020; 10
Janoniene (10.1016/j.addr.2021.113891_b0690) 2017; 9
Cui (10.1016/j.addr.2021.113891_b0245) 2021; 40
Gothwal (10.1016/j.addr.2021.113891_b0525) 2016; 33
de Lazaro (10.1016/j.addr.2021.113891_b0810) 2021
Chen (10.1016/j.addr.2021.113891_b0030) 2019; 447
Lu (10.1016/j.addr.2021.113891_b0340) 2020; 10
Zhan (10.1016/j.addr.2021.113891_b0045) 2019; 55
Simbulan-Rosenthal (10.1016/j.addr.2021.113891_b0360) 2019; 11
Mi (10.1016/j.addr.2021.113891_b0535) 2011; 32
Nguyen (10.1016/j.addr.2021.113891_b0585) 2013; 9
Pedro (10.1016/j.addr.2021.113891_b0830) 2019; 16
Xiao (10.1016/j.addr.2021.113891_b0430) 2018; 51
Foroozandeh (10.1016/j.addr.2021.113891_b1280) 2018; 13
Shukla (10.1016/j.addr.2021.113891_b1250) 2012; 109
Es (10.1016/j.addr.2021.113891_b0160) 2019; 37
Azangou-Khyavy (10.1016/j.addr.2021.113891_b0180) 2020; 11
de Oliveira (10.1016/j.addr.2021.113891_b0920) 2020; 10
Aina (10.1016/j.addr.2021.113891_b1170) 2002; 66
Zhu (10.1016/j.addr.2021.113891_b1070) 2018; 134
Suk (10.1016/j.addr.2021.113891_b0930) 2016; 99
Hazafa (10.1016/j.addr.2021.113891_b0130) 2020; 263
Zuris (10.1016/j.addr.2021.113891_b0640) 2015; 33
Muhamad (10.1016/j.addr.2021.113891_b1015) 2018; 13
Sengupta (10.1016/j.addr.2021.113891_b1120) 2019; 2
Iturrioz-Rodriguez (10.1016/j.addr.2021.113891_b0700) 2019; 14
Lu (10.1016/j.addr.2021.113891_b0185) 2020; 26
Bouche (10.1016/j.addr.2021.113891_b0770) 2020; 31
Basha (10.1016/j.addr.2021.113891_b0505) 2018; 15
Ouyang (10.1016/j.addr.2021.113891_b0330) 2019; 9
Trac (10.1016/j.addr.2021.113891_b1180) 2020; 5
Li (10.1016/j.addr.2021.113891_b1195) 2017; 11
Cai (10.1016/j.addr.2021.113891_b0795) 2016; 8
Patil (10.1016/j.addr.2021.113891_b1295) 2011; 5
Sun (10.1016/j.addr.2021.113891_b0295) 2018; 98
Sun (10.1016/j.addr.2021.113891_b0900) 2015; 54
Sharma (10.1016/j.addr.2021.113891_b0560) 2020; 10
Guo (10.1016/j.addr.2021.113891_b1340) 2019; 116
Ishino (10.1016/j.addr.2021.113891_b0085) 1987; 169
Song (10.1016/j.addr.2021.113891_b0515) 2018; 12
Garcia-Peterson (10.1016/j.addr.2021.113891_b0355) 2020; 96
Xu (10.1016/j.addr.2021.113891_b0825) 2020; 12
Kulkarni (10.1016/j.addr.2021.113891_b1315) 2018; 28
Roy (10.1016/j.addr.2021.113891_b1290) 2020; 14
Zhen (10.1016/j.addr.2021.113891_b1130) 2017; 8
Bakke (10.1016/j.addr.2021.113891_b0420) 2019; 19
Xu (10.1016/j.addr.2021.113891_b0065) 2019; 21
Zhao (10.1016/j.addr.2021.113891_b0325) 2017; 8
Friedmann (10.1016/j.addr.2021.113891_b0020) 1992; 70
Moore (10.1016/j.addr.2021.113891_b0210) 2020; 19
Zhang (10.1016/j.addr.2021.113891_b0955) 2017; 9
Chen (10.1016/j.addr.2021.113891_b0755) 2018; 3
Probst (10.1016/j.addr.2021.113891_b0790) 2013; 65
Peng (10.1016/j.addr.2021.113891_b0750) 2019; 58
Ramakrishna (10.1016/j.addr.2021.113891_b0840) 2014; 24
Deveau (10.1016/j.addr.2021.113891_b0115) 2008; 190
Li (10.1016/j.addr.2021.113891_b0685) 2018; 30
Pi (10.1016/j.addr.2021.113891_b1140) 2018; 13
Jubair (10.1016/j.addr.2021.113891_b0950) 2019; 27
Witte (10.1016/j.addr.2021.113891_b0375) 2020; 10
He (10.1016/j.addr.2021.113891_b1240) 2018; 29
Zhou (10.1016/j.addr.2021.113891_b1420) 2018; 19
Aaghaz (10.1016/j.addr.2021.113891_b0495) 2019; 19
Moosavian (10.1016/j.addr.2021.113891_b1085) 2019; 448
Haran (10.1016/j.addr.2021.113891_b0660) 1994; 1190
Zhang (10.1016/j.addr.2021.113891_b0705) 2017; 23
Cimadamore (10.1016/j.addr.2021.113891_b1115) 2018; 8
Li (10.1016/j.addr.2021.113891_b0800) 2018; 171
Rosenblum (10.1016/j.addr.2021.113891_b0990) 2018; 9
Seleci (10.1016/j.addr.2021.113891_b0655) 2019; 20
Cai (10.1016/j.addr.2021.113891_b1375) 2020
Chen (10.1016/j.addr.2021.113891_b1395) 2019; 14
Wojnilowicz (10.1016/j.addr.2021.113891_b1285) 2019; 13
Wang (10.1016/j.addr.2021.113891_b1370) 2020; 324
Wu (10.1016/j.addr.2021.113891_b0205) 2020; 39
Behan (10.1016/j.addr.2021.113891_b0465) 2019; 568
Lee (10.1016/j.addr.2021.113891_b1005) 2016; 6
Wei (10.1016/j.addr.2021.113891_b0765) 2021
He (10.1016/j.addr.2021.113891_b0855) 2020; 32
He (10.1016/j.addr.2021.113891_b1100) 2019; 11
Sun (10.1016/j.addr.2021.113891_b0580) 2020; 17
Lin (10.1016/j.addr.2021.113891_b0145) 2014; 3
Poddar (10.1016/j.addr.2021.113891_b1265) 2020; 56
Bertrand (10.1016/j.addr.2021.113891_b1000) 2014; 66
Gillmore (10.1016/j.addr.2021.113891_b0480) 2021
Moghassemi (10.1016/j.addr.2021.113891_b0645) 2014; 185
Xu (10.1016/j.addr.2021.113891_b1065) 2020; 326
Lyu (10.1016/j.addr.2021.113891_b1435) 2019
Kim (10.1016/j.addr.2021.113891_b0380) 2021; 54
Shi (10.1016/j.addr.2021.113891_b0530) 2015; 9
Wang (10.1016/j.addr.2021.113891_b0865) 2015; 44
Slotta (10.1016/j.addr.2021.113891_b0460) 2017; 12
Mandal (10.1016/j.addr.2021.113891_b0720) 2018; 18
Rizk (10.1016/j.addr.2021.113891_b0775) 2016; 27
Wang (10.1016/j.addr.2021.113891_b0835) 2016; 11
Yi (10.1016/j.addr.2021.113891_b0010) 1866; 2016
Zhou (10.1016/j.addr.2021.113891_b0285) 2020; 146
Wang (10.1016/j.addr.2021.113891_b0610) 2017; 86
Zhu (10.1016/j.addr.2021.113891_b0710) 2009; 19
Lao (10.1016/j.addr.2021.113891_b0965) 2018; 5
Zhuang (10.1016/j.addr.2021.113891_b1155) 2020; 48
Wu (10.1016/j.addr.2021.113891_b0310) 2016; 36
Wan (10.1016/j.addr.2021.113891_b0850) 2020; 322
Zhao (10.1016/j.addr.2021.113891_b0335) 2018; 11
Russo (10.1016/j.addr.2021.113891_b0225) 2003; 22
Castro (10.1016/j.addr.2021.113
References_xml – volume: 38
  start-page: 6399
  year: 2019
  end-page: 6413
  ident: b0235
  article-title: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
  publication-title: Oncogene
– volume: 10
  year: 2018
  ident: b0520
  article-title: Micelles structure development as a strategy to improve smart cancer therapy
  publication-title: Cancers
– volume: 266
  start-page: 17
  year: 2017
  end-page: 26
  ident: b0060
  article-title: Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
  publication-title: J. Control. Release
– volume: 27
  start-page: 1461
  year: 2020
  end-page: 1473
  ident: b0680
  article-title: A sustained dual drug delivery system for proliferative vitreoretinopathy
  publication-title: Drug Deliv.
– volume: 9
  start-page: 535
  year: 2014
  end-page: 554
  ident: b0670
  article-title: Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications
  publication-title: Nanomedicine-Uk
– volume: 32
  year: 2020
  ident: b1040
  article-title: Cancer-targeting nanoparticles for combinatorial nucleic acid delivery
  publication-title: Adv. Mater.
– volume: 51
  start-page: 1879
  year: 2018
  end-page: 1893
  ident: b0430
  article-title: Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells
  publication-title: Cell. Physiol. Biochem.
– volume: 145
  start-page: 182
  year: 2010
  end-page: 195
  ident: b1325
  article-title: Endocytosis of nanomedicines
  publication-title: J. Control. Release
– volume: 6
  year: 2015
  ident: b0630
  article-title: Advances and challenges of liposome assisted drug delivery
  publication-title: Front. Pharmacol.
– volume: 31
  year: 2019
  ident: b1350
  article-title: Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity
  publication-title: Adv. Mater.
– volume: 9
  start-page: 3740
  year: 2015
  end-page: 3752
  ident: b0530
  article-title: Complete regression of xenograft tumors upon targeted delivery of paclitaxel via Pi-Pi stacking stabilized polymeric micelles
  publication-title: ACS Nano
– volume: 14
  year: 2018
  ident: b1360
  article-title: Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids
  publication-title: Small
– volume: 12
  start-page: 21001
  year: 2020
  end-page: 21014
  ident: b0825
  article-title: Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
  publication-title: Nanoscale
– volume: 11
  start-page: 9
  year: 2016
  end-page: 30
  ident: b1255
  article-title: EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment
  publication-title: Nanomedicine-Uk
– volume: 52
  start-page: 1750
  year: 2019
  end-page: 1760
  ident: b1270
  article-title: Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors
  publication-title: Accounts Chem. Res.
– volume: 140
  start-page: 6596
  year: 2018
  end-page: 6603
  ident: b1275
  article-title: Receptor-mediated delivery of CRISPR-Cas9 endonuclease for cell-type-specific gene editing
  publication-title: J. Am. Chem. Soc.
– volume: 14
  start-page: 3389
  year: 2019
  end-page: 3401
  ident: b0700
  article-title: Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles
  publication-title: Int. J. Nanomed.
– volume: 31
  start-page: 309
  year: 2020
  end-page: 324
  ident: b1355
  article-title: Human papillomavirus oncogene manipulation using clustered regularly interspersed short palindromic repeats/Cas9 delivered by pH-sensitive cationic liposomes
  publication-title: Hum. Gene Ther.
– volume: I
  start-page: 540
  year: 2020
  end-page: 544
  ident: b0255
  article-title: Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids
  publication-title: Jnci-J. Natl. Cancer
– volume: 291
  start-page: 90
  year: 2018
  end-page: 98
  ident: b1095
  article-title: Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors
  publication-title: J. Control. Release
– volume: 54
  year: 2021
  ident: b0380
  article-title: The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids
  publication-title: Cell Proliferat
– volume: 8
  start-page: 33300
  year: 2017
  end-page: 33315
  ident: b0240
  article-title: IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
  publication-title: Oncotarget
– volume: 39
  start-page: 795
  year: 2018
  end-page: 801
  ident: b0455
  article-title: Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells
  publication-title: Oncol. Rep.
– volume: 19
  start-page: 1491
  year: 2019
  end-page: 1511
  ident: b0495
  article-title: Peptides as potential anticancer agents
  publication-title: Curr. Top. Med. Chem.
– volume: 4
  year: 2017
  ident: b0895
  article-title: Genome editing for cancer therapy: delivery of Cas9 Protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier
  publication-title: Adv. Sci.
– volume: 60
  start-page: 174
  year: 2005
  end-page: 182
  ident: b0095
  article-title: Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements
  publication-title: J. Mol. Evol.
– volume: 23
  start-page: 3367
  year: 2017
  end-page: 3382
  ident: b0705
  article-title: Advances in functionalized mesoporous silica nanoparticles for tumor targeted drug delivery and theranostics
  publication-title: Curr. Pharm. Des.
– volume: 40
  start-page: 177
  year: 2021
  end-page: 188
  ident: b0315
  article-title: Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth
  publication-title: Oncogene
– volume: 11
  start-page: 2352
  year: 2015
  end-page: 2364
  ident: b1150
  article-title: Aptamers and their applications in nanomedicine
  publication-title: Small
– volume: 48
  start-page: 8870
  year: 2020
  end-page: 8882
  ident: b1155
  article-title: Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy
  publication-title: Nucleic Acids Res.
– volume: 8
  start-page: 47020
  year: 2017
  end-page: 47036
  ident: b0320
  article-title: Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer
  publication-title: Oncotarget
– volume: 36
  start-page: 1211
  year: 2016
  end-page: 1219
  ident: b0310
  article-title: Knockdown of EPHA1 by CRISPR/CAS9 promotes adhesion and motility of HRT18 colorectal carcinoma cells
  publication-title: Anticancer Res.
– volume: 29
  start-page: 223
  year: 2018
  end-page: 233
  ident: b1240
  article-title: In vivo ovarian cancer gene therapy using CRISPR-Cas9
  publication-title: Hum. Gene Ther.
– volume: 7
  start-page: 83502
  year: 2016
  end-page: 83513
  ident: b0435
  article-title: Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
  publication-title: Oncotarget
– volume: 117
  start-page: 2395
  year: 2020
  end-page: 2405
  ident: b1450
  article-title: Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing
  publication-title: P. Natl. Acad. Sci. USA
– volume: 7
  year: 2020
  ident: b0745
  article-title: Redox-responsive tumor targeted dual-drug loaded biocompatible metal–organic frameworks nanoparticles for enhancing anticancer effects
  publication-title: BMC Mat.
– volume: 26
  start-page: 782-+
  year: 2020
  ident: b0200
  article-title: Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids
  publication-title: Cell Stem Cell
– volume: 52
  start-page: 198-+
  year: 2020
  ident: b0190
  article-title: ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
  publication-title: Nat. Genet.
– volume: 37
  start-page: 789
  year: 2019
  end-page: 798
  ident: b0440
  article-title: Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma
  publication-title: J. Orthop. Res.
– volume: 9
  year: 2017
  ident: b0955
  article-title: Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
  publication-title: NPG Asia Mater.
– volume: 190
  start-page: 1390
  year: 2008
  end-page: 1400
  ident: b0115
  article-title: Phage response to CRISPR-Encoded resistance in Streptococcus thermophilus
  publication-title: J. Bacteriol.
– volume: 10
  start-page: 1440
  year: 2019
  end-page: 1457
  ident: b0305
  article-title: CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition
  publication-title: Oncotarget
– volume: 83
  start-page: 3080
  year: 2020
  end-page: 3092
  ident: b0270
  article-title: CRISPR-Cas9 genome-wide knockout screen identifies mechanism of selective activity of dehydrofalcarinol in mesenchymal stem-like triple-negative breast cancer cells
  publication-title: J. Nat. Prod.
– volume: 53
  start-page: 12320
  year: 2014
  end-page: 12364
  ident: b1220
  article-title: Engineered nanoparticles for drug delivery in cancer therapy
  publication-title: Angew. Chem. Int. Ed.
– volume: 146
  start-page: 1509
  year: 2020
  end-page: 1521
  ident: b0285
  article-title: Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively
  publication-title: J. Cancer Res. Clin.
– volume: 145
  start-page: 192
  year: 2019
  end-page: 205
  ident: b0425
  article-title: Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality
  publication-title: Int. J. Cancer
– volume: 8
  start-page: 22442
  year: 2016
  end-page: 22450
  ident: b0795
  article-title: pH-sensitive ZnO quantum dots-doxorubicin nanoparticles for lung cancer targeted drug delivery
  publication-title: Acs Appl Mater Inter
– volume: 24
  start-page: 955
  year: 2019
  end-page: 970
  ident: b0165
  article-title: CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
  publication-title: Drug Discov. Today
– volume: 19
  start-page: 7765
  year: 2009
  end-page: 7770
  ident: b0710
  article-title: An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates
  publication-title: J. Mater. Chem.
– volume: 11
  start-page: 11136
  year: 2019
  end-page: 11147
  ident: b0395
  article-title: Ninjurin2 overexpression promotes glioma cell growth
  publication-title: Aging-Us
– volume: 9
  year: 2020
  ident: b1125
  article-title: Selective targeting of the hedgehog signaling pathway by PBM nanoparticles in docetaxel-resistant prostate cancer
  publication-title: Cells-Basel
– volume: 32
  start-page: 1909
  year: 2017
  end-page: 1918
  ident: b1425
  article-title: Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods
  publication-title: Laser Med. Sci.
– volume: 8
  year: 2018
  ident: b1115
  article-title: New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen
  publication-title: Front. Oncol.
– volume: 13
  start-page: 3921
  year: 2018
  end-page: 3935
  ident: b1015
  article-title: Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review
  publication-title: Int. J. Nanomed.
– volume: 9
  year: 2019
  ident: b0385
  article-title: Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion
  publication-title: Sci. Rep.-Uk
– volume: 12
  year: 2020
  ident: b0735
  article-title: Metal-organic framework nanocarriers for drug delivery in biomedical applications
  publication-title: Nano-Micro Lett.
– volume: 12
  start-page: 278
  year: 2012
  end-page: 287
  ident: b1020
  article-title: Antibody therapy of cancer
  publication-title: Nat. Rev. Cancer
– volume: 9
  year: 2020
  ident: b1050
  article-title: Adult stem cell-derived extracellular vesicles in cancer treatment: opportunities and challenges
  publication-title: Cells-Basel
– volume: 14
  start-page: 601
  year: 2021
  end-page: 610
  ident: b1415
  article-title: Chain-shattering Pt(IV)-backboned polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic cancer therapy
  publication-title: Nano Res.
– volume: 49
  start-page: 2273
  year: 2020
  end-page: 2290
  ident: b0910
  article-title: Influence of nanomedicine mechanical properties on tumor targeting delivery
  publication-title: Chem. Soc. Rev.
– volume: 5
  year: 2020
  ident: b0275
  article-title: CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells
  publication-title: Bioeng. Transl. Med.
– volume: 392
  year: 2020
  ident: b1055
  article-title: Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib
  publication-title: Exp. Cell Res.
– volume: 151
  start-page: 2551
  year: 2005
  end-page: 2561
  ident: b0100
  article-title: Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin
  publication-title: Microbiol-Sgm
– volume: 68
  start-page: 165
  year: 2017
  end-page: 174
  ident: b0490
  article-title: Drug delivery systems improving chemical and physical properties of anticancer drugs currently investigated for treatment of solid tumors
  publication-title: J. Physiol. Pharmacol.
– volume: 106
  start-page: 148
  year: 2016
  end-page: 156
  ident: b1045
  article-title: Extracellular vesicles for drug delivery
  publication-title: Adv. Drug Deliver. Rev.
– volume: 19
  year: 2019
  ident: b0420
  article-title: Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells
  publication-title: Bmc Cancer
– volume: 30
  year: 2018
  ident: b0685
  article-title: Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy
  publication-title: Adv. Mater.
– volume: 510
  start-page: 235-+
  year: 2014
  ident: b0150
  article-title: Targeted genome editing in human repopulating haematopoietic stem cells
  publication-title: Nature
– volume: 5
  year: 2018
  ident: b0965
  article-title: HPV Oncogene Manipulation Using Nonvirally Delivered CRISPR/Cas9 or Natronobacterium gregoryi Argonaute
  publication-title: Adv. Sci.
– volume: 17
  start-page: 373
  year: 2020
  end-page: 391
  ident: b0580
  article-title: Hydrogel-based controlled drug delivery for cancer treatment: a review
  publication-title: Mol. Pharmaceut.
– volume: 466
  start-page: 1441
  year: 2010
  end-page: 1443
  ident: b0540
  article-title: Unique structure and property of dendrimers in biomedical applications INTRODUCTION
  publication-title: P. Roy. Soc. a-Math. Phy.
– volume: 6
  year: 2019
  ident: b0960
  article-title: Multistage delivery nanoparticle facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo
  publication-title: Adv. Sci.
– volume: 15
  start-page: 497
  year: 2018
  end-page: 509
  ident: b0505
  article-title: Nanotechnology as a promising strategy for anticancer drug delivery
  publication-title: Curr. Drug Deliv.
– volume: 3
  year: 2014
  ident: b0145
  article-title: Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
  publication-title: Elife
– volume: 367
  start-page: 525-+
  year: 2020
  ident: b0470
  article-title: Neoadjuvant checkpoint blockade for cancer immunotherapy
  publication-title: Science
– volume: 99
  start-page: 28
  year: 2016
  end-page: 51
  ident: b0930
  article-title: PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
  publication-title: Adv. Drug Deliver. Rev.
– volume: 326
  start-page: 455
  year: 2020
  end-page: 467
  ident: b1065
  article-title: Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies
  publication-title: J. Control. Release
– volume: 22
  start-page: 6959
  year: 2003
  end-page: 6969
  ident: b0225
  article-title: pRB(2)/p130 target genes in non-small lung cancer cells identified by microarray analysis
  publication-title: Oncogene
– volume: 16
  year: 2021
  ident: b0080
  article-title: Inorganic porous nanoparticles for drug delivery in antitumoral therapy
  publication-title: Biotechnol. J.
– volume: 324
  start-page: 194
  year: 2020
  end-page: 203
  ident: b1370
  article-title: A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries
  publication-title: J. Control. Release
– volume: 447
  start-page: 48
  year: 2019
  end-page: 55
  ident: b0030
  article-title: CRISPR-Cas9 for cancer therapy: Opportunities and challenges
  publication-title: Cancer Lett.
– volume: 111
  start-page: 76
  year: 2019
  end-page: 85
  ident: b0400
  article-title: CRISPR/Cas9-mediated knockout of the PDEF gene inhibits migration and invasion of human gastric cancer AGS cells
  publication-title: Biomed. Pharmacother.
– volume: 168
  start-page: 3
  year: 2021
  end-page: 29
  ident: b0805
  article-title: Rational designs of in vivo CRISPR-Cas delivery systems
  publication-title: Adv. Drug Deliver. Rev.
– volume: 27
  year: 2020
  ident: b1105
  article-title: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex (vol 22, 4, 2015)
  publication-title: J. Biomed. Sci.
– volume: 27
  year: 2017
  ident: b1215
  article-title: Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles
  publication-title: Adv. Funct. Mater.
– volume: 249
  start-page: 505
  year: 1990
  end-page: 510
  ident: b1075
  article-title: Systematic evolution of ligands by exponential enrichment - rna ligands to bacteriophage-T4 DNA-polymerase
  publication-title: Science
– volume: 10
  start-page: 4557
  year: 2020
  end-page: 4588
  ident: b1380
  article-title: Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
  publication-title: Theranostics
– volume: 14
  start-page: 2817
  year: 2020
  end-page: 2826
  ident: b1445
  article-title: A genome-editing nanomachine constructed with a clustered regularly interspaced short palindromic repeats system and activated by near-infrared illumination
  publication-title: ACS Nano
– volume: 2016
  start-page: 197
  year: 1866
  end-page: 207
  ident: b0010
  article-title: CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
  publication-title: Bba-Rev. Cancer
– volume: 230
  year: 2020
  ident: b0730
  article-title: Metal-organic frameworks for stimuli-responsive drug delivery
  publication-title: Biomaterials
– volume: 1
  year: 2016
  ident: b0995
  article-title: Analysis of nanoparticle delivery to tumours
  publication-title: Nat. Rev. Mater.
– volume: 142
  start-page: 40
  year: 2010
  end-page: 46
  ident: b0565
  article-title: pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles
  publication-title: J. Control. Release
– volume: 315
  start-page: 1709
  year: 2007
  end-page: 1712
  ident: b0105
  article-title: CRISPR provides acquired resistance against viruses in prokaryotes
  publication-title: Science
– volume: 9
  year: 2019
  ident: b1090
  article-title: Aptamer-based targeted delivery of a g-quadruplex ligand in cervical cancer cells
  publication-title: Sci. Rep.-Uk
– volume: 13
  year: 2018
  ident: b1280
  article-title: Insight into cellular uptake and intracellular trafficking of nanoparticles
  publication-title: Nanoscale Res. Lett.
– volume: 321
  start-page: 285
  year: 2020
  end-page: 311
  ident: b0875
  article-title: Synthesis and functionalization of hyperbranched polymers for targeted drug delivery
  publication-title: J. Control. Release
– volume: 321
  start-page: 654
  year: 2020
  end-page: 668
  ident: b0885
  article-title: Hyperbranched poly(beta-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer
  publication-title: J. Control. Release
– volume: 27
  year: 2016
  ident: b0775
  article-title: Optimization of anti-cancer drugs and a targeting molecule on multifunctional gold nanoparticles
  publication-title: Nanotechnology
– volume: 19
  start-page: 1840
  year: 2018
  end-page: 1857
  ident: b1420
  article-title: Photoresponsive drug/gene delivery systems
  publication-title: Biomacromolecules
– volume: 25
  start-page: 1837
  year: 2018
  end-page: 1866
  ident: b1345
  article-title: Stimuli responsive nanoparticles for controlled anti-cancer drug release
  publication-title: Curr. Med. Chem.
– volume: 2
  year: 2019
  ident: b1120
  article-title: Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer
  publication-title: Cancer Rep.-Us
– volume: 9
  start-page: 44045
  year: 2017
  end-page: 44052
  ident: b0945
  article-title: Tumor-targeted accumulation of ligand-installed polymeric micelles influenced by surface PEGylation crowdedness
  publication-title: Acs Appl. Mater. Inter.
– volume: 13
  start-page: 4727
  year: 2018
  end-page: 4745
  ident: b0485
  article-title: Recent advances in “smart” delivery systems for extended drug release in cancer therapy
  publication-title: Int. J. Nanomed.
– volume: 339
  start-page: 823
  year: 2013
  end-page: 826
  ident: b0040
  article-title: RNA-Guided Human Genome Engineering via Cas9
  publication-title: Science
– volume: 16
  start-page: 6823
  year: 2016
  end-page: 6831
  ident: b0970
  article-title: Ultrasensitive pH triggered charge/size dual-rebound gene delivery system
  publication-title: Nano Lett.
– volume: 32
  year: 2020
  ident: b0855
  article-title: Aptamer/peptide-functionalized genome-editing system for effective immune restoration through reversal of PD-L1-mediated cancer immunosuppression
  publication-title: Adv. Mater.
– volume: 8
  year: 2017
  ident: b1470
  article-title: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome
  publication-title: Front. Pharmacol.
– volume: 31
  start-page: 303
  year: 2020
  end-page: 314
  ident: b0770
  article-title: Recent advances in molecular imaging with gold nanoparticles
  publication-title: Bioconjug. Chem.
– volume: 19
  start-page: 495
  year: 2019
  end-page: 509
  ident: b0170
  article-title: Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
  publication-title: Nat. Rev. Cancer
– volume: 141
  start-page: 9937
  year: 2019
  end-page: 9945
  ident: b1400
  article-title: Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy
  publication-title: J. Am. Chem. Soc.
– volume: 4
  start-page: 958
  year: 2016
  end-page: 969
  ident: b0550
  article-title: Fabrication of dendrimer-releasing lipidic nanoassembly for cancer drug delivery
  publication-title: Biomater. Sci-Uk
– volume: 448
  start-page: 144
  year: 2019
  end-page: 154
  ident: b1085
  article-title: Aptamer-functionalized liposomes for targeted cancer therapy
  publication-title: Cancer Lett.
– volume: 1190
  start-page: 197
  year: 1994
  ident: b0660
  article-title: Transmembrane ammonium-sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases
  publication-title: Bba-Biomembranes
– volume: 5
  year: 2019
  ident: b0905
  article-title: A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing
  publication-title: Sci. Adv.
– volume: 11
  start-page: 95
  year: 2017
  end-page: 111
  ident: b1195
  article-title: Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice
  publication-title: ACS Nano
– volume: 37
  start-page: 1518
  year: 2017
  end-page: 1539
  ident: b1080
  article-title: Anti-MUC1 aptamer: a potential opportunity for cancer treatment
  publication-title: Med. Res. Rev.
– volume: 13
  start-page: 288
  year: 2018
  end-page: 303
  ident: b0595
  article-title: Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages
  publication-title: Res. Pharm. Sci.
– volume: 70
  start-page: 1810
  year: 1992
  end-page: 1817
  ident: b0020
  article-title: Gene-therapy of cancer through restoration of tumor-suppressor functions
  publication-title: Cancer
– volume: 258
  year: 2020
  ident: b1475
  article-title: Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy
  publication-title: Biomaterials
– volume: 12
  start-page: 145
  year: 2011
  end-page: 155
  ident: b0870
  article-title: Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin
  publication-title: Biomacromolecules
– volume: 32
  start-page: 4058
  year: 2011
  end-page: 4066
  ident: b0535
  article-title: Formulation of Docetaxel by folic acid-conjugated D-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy
  publication-title: Biomaterials
– volume: 330
  start-page: 502
  year: 2021
  end-page: 528
  ident: b0555
  article-title: Self-assembled polymeric vesicles: focus on polymersomes in cancer treatment
  publication-title: J. Control. Release
– volume: 9
  start-page: 4487
  year: 2013
  end-page: 4495
  ident: b0585
  article-title: Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells
  publication-title: Acta Biomater.
– volume: 147
  start-page: 68
  year: 2017
  end-page: 85
  ident: b1135
  article-title: Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma
  publication-title: Biomaterials
– volume: 5
  year: 2015
  ident: b0740
  article-title: Aptamer-mediated up-conversion core/MOF shell nanocomposites for targeted drug delivery and cell imaging
  publication-title: Sci. Rep.-Uk
– volume: 31
  year: 2019
  ident: b1385
  article-title: Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles
  publication-title: Adv. Mater.
– volume: 40
  start-page: 909
  year: 2021
  end-page: 921
  ident: b0245
  article-title: NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration
  publication-title: Oncogene
– volume: 14
  start-page: 476
  year: 2013
  end-page: 484
  ident: b1235
  article-title: Folic Acid Modified Cationic gamma-Cyclodextrin-oligoethylenimine Star Polymer with Bioreducible Disulfide Linker for Efficient Targeted Gene Delivery
  publication-title: Biomacromolecules
– volume: 20
  year: 2019
  ident: b0655
  article-title: Rapid microfluidic preparation of niosomes for targeted drug delivery
  publication-title: Int. J. Mol. Sci.
– volume: 86
  start-page: 595
  year: 2017
  end-page: 604
  ident: b0610
  article-title: Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer
  publication-title: Biomed. Pharmacother.
– volume: 57
  start-page: 7131
  year: 2018
  end-page: 7135
  ident: b1160
  article-title: Valency-controlled framework nucleic acid signal amplifiers
  publication-title: Angew. Chem. Int. Ed.
– volume: 12
  start-page: 2437
  year: 2019
  end-page: 2450
  ident: b0075
  article-title: Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect
  publication-title: Nano Res.
– volume: 33
  start-page: 8759
  year: 2019
  end-page: 8770
  ident: b0300
  article-title: Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth
  publication-title: FASEB J.
– volume: 6
  start-page: 177
  year: 2016
  end-page: 191
  ident: b1205
  article-title: Dual receptor recognizing cell penetrating peptide for selective targeting efficient intratumoral diffusion and synthesized anti-glioma therapy
  publication-title: Theranostics
– volume: 42
  start-page: 419
  year: 2003
  end-page: 436
  ident: b0935
  article-title: Pharmacokinetics of pegylated liposomal doxorubicin - review of animal and human studies
  publication-title: Clin. Pharmacokinet.
– volume: 16
  start-page: 510
  year: 2009
  end-page: 520
  ident: b1210
  article-title: Tissue-penetrating delivery of compounds and nanoparticles into tumors
  publication-title: Cancer Cell
– volume: 12
  start-page: 16018
  year: 2020
  end-page: 16030
  ident: b1490
  article-title: Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death
  publication-title: Acs Appl. Mater. Inter.
– volume: 10
  start-page: 1688
  year: 2020
  end-page: 1699
  ident: b0920
  article-title: Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating
  publication-title: Drug Deliv. Transl. Re.
– volume: 12
  start-page: 57362
  year: 2020
  end-page: 57372
  ident: b0290
  article-title: Co-delivery of sorafenib and CRISPR/Cas9 based on targeted core-shell hollow mesoporous organosilica nanoparticles for synergistic HCC therapy
  publication-title: Acs Appl. Mater. Inter.
– volume: 80
  start-page: 404
  year: 2019
  end-page: 424
  ident: b1225
  article-title: Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems
  publication-title: Drug Develop. Res.
– volume: 463
  start-page: 568
  year: 2010
  end-page: U194
  ident: b0120
  article-title: Self versus non-self discrimination during CRISPR RNA-directed immunity
  publication-title: Nature
– volume: 140
  start-page: 143
  year: 2018
  end-page: 146
  ident: b1300
  article-title: Endosomal escape and delivery of CRISPR/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework
  publication-title: J. Am. Chem. Soc.
– volume: 10
  start-page: 1171
  year: 2020
  end-page: 1190
  ident: b0560
  article-title: Emerging era of “somes”: polymersomes as versatile drug delivery carrier for cancer diagnostics and therapy
  publication-title: Drug Deliv. Transl. Re
– volume: 10
  year: 2020
  ident: b0345
  article-title: Knockout ofEGFL6by CRISPR/Cas9 mediated inhibition of tumor angiogenesis in ovarian cancer
  publication-title: Front. Oncol.
– volume: 116
  start-page: 255
  year: 2006
  end-page: 264
  ident: b1320
  article-title: Cationic lipids, lipoplexes and intracellular delivery of genes
  publication-title: J. Control. Release
– volume: 11
  start-page: 226
  year: 2019
  end-page: 237
  ident: b1100
  article-title: Multifunctional vector for delivery of genome editing plasmid targeting beta-catenin to remodulate cancer cell properties
  publication-title: Acs Appl. Mater. Inter.
– volume: 56
  year: 2020
  ident: b1265
  article-title: ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer
  publication-title: Chem. Commun.
– volume: 181
  start-page: 151
  year: 2020
  end-page: 167
  ident: b1010
  article-title: Targeting strategies for tissue-specific drug delivery
  publication-title: Cell
– volume: 33
  start-page: 73
  year: 2015
  end-page: 80
  ident: b0640
  article-title: Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
  publication-title: Nat. Biotechnol.
– volume: 13
  year: 2018
  ident: b0260
  article-title: CRISPR deletion of MIEN1 in breast cancer cells
  publication-title: PLoS ONE
– volume: 9
  year: 2020
  ident: b1460
  article-title: Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology
  publication-title: Cells-Basel
– volume: 29
  year: 2017
  ident: b0510
  article-title: Metal-organic framework (MOF)-based drug/cargo delivery and cancer therapy
  publication-title: Adv. Mater.
– volume: 11
  year: 2020
  ident: b0140
  article-title: A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice
  publication-title: Nat. Commun.
– volume: 24
  start-page: 1020
  year: 2014
  end-page: 1027
  ident: b0840
  article-title: Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
  publication-title: Genome Res.
– year: 2021
  ident: b0810
  article-title: Obstacles and opportunities in a forward vision for cancer nanomedicine
  publication-title: Nat. Mater.
– volume: 5
  year: 2019
  ident: b1430
  article-title: Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform
  publication-title: Sci. Adv.
– volume: 20
  start-page: 555
  year: 2020
  end-page: 572
  ident: b0175
  article-title: A compendium of mutational cancer driver genes
  publication-title: Nat. Rev. Cancer
– volume: 33
  start-page: 18
  year: 2016
  end-page: 39
  ident: b0525
  article-title: Polymeric micelles: recent advancements in the delivery of anticancer drugs
  publication-title: Pharm. Res.-Dordr.
– volume: 18
  start-page: 649
  year: 2017
  end-page: 673
  ident: b0570
  article-title: Stimuli-responsive polymersomes for biomedical applications
  publication-title: Biomacromolecules
– year: 2020
  ident: b1375
  article-title: Spatiotemporal delivery of CRISPR/Cas9 genome editing machinery using stimuli-responsive vehicles
  publication-title: Angew. Chem. Int. Ed.
– volume: 304
  start-page: 204
  year: 2019
  end-page: 215
  ident: b0415
  article-title: Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer
  publication-title: J. Control. Release
– volume: 9
  start-page: 907
  year: 2014
  end-page: 912
  ident: b1260
  article-title: Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy
  publication-title: Nat. Nanotechnol.
– volume: 3
  start-page: 347
  year: 2018
  end-page: 354
  ident: b0755
  article-title: Doxorubicin-conjugated pH-responsive gold nanorods for combined photothermal therapy and chemotherapy of cancer
  publication-title: Bioact. Mater.
– volume: 141
  start-page: 19032
  year: 2019
  end-page: 19037
  ident: b1410
  article-title: A self-assembled platform based on branched DNA for sgRNA/Cas9/antisense delivery
  publication-title: J. Am. Chem. Soc.
– volume: 252
  start-page: 3582
  year: 1977
  end-page: 3586
  ident: b0915
  article-title: Effect of covalent attachment of polyethylene-glycol on immunogenicity and circulating life of bovine liver catalase
  publication-title: J. Biol. Chem.
– volume: 39
  year: 2020
  ident: b0205
  article-title: Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
  publication-title: J Exp Clin Canc Res
– volume: 6
  start-page: 1118
  year: 2016
  end-page: 1134
  ident: b1005
  article-title: Nanoparticle-based targeted gene therapy for lung cancer
  publication-title: Am. J. Cancer Res.
– volume: 11
  start-page: 133
  year: 2016
  end-page: 144
  ident: b0835
  article-title: Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines
  publication-title: Nano Today
– volume: 116
  start-page: 18295
  year: 2019
  end-page: 18303
  ident: b1340
  article-title: Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel
  publication-title: P Natl Acad Sci USA
– volume: 8
  start-page: 2274
  year: 2020
  end-page: 2282
  ident: b1175
  article-title: Tumor-targeting peptide functionalized PEG-PLA micelles for efficient drug delivery
  publication-title: Biomater Sci-Uk
– volume: 9
  year: 2017
  ident: b1185
  article-title: Exploring the role of RGD-recognizing integrins in cancer
  publication-title: Cancers
– volume: 3
  start-page: 217
  year: 2018
  end-page: 228
  ident: b0125
  article-title: Blossom of CRISPR technologies and applications in disease treatment
  publication-title: Syn. Syst. Biotechno.
– volume: 7
  start-page: 500
  year: 2013
  end-page: 512
  ident: b0815
  article-title: Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging
  publication-title: ACS Nano
– volume: 169
  start-page: 5429
  year: 1987
  end-page: 5433
  ident: b0085
  article-title: Nucleotide-Sequence of the Iap Gene, Responsible for Alkaline-Phosphatase Isozyme Conversion in Escherichia-Coli, and Identification of the Gene-Product
  publication-title: J. Bacteriol.
– volume: 26
  year: 2020
  ident: b0185
  article-title: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
  publication-title: Nat. Med.
– volume: 11
  start-page: 34717
  year: 2019
  end-page: 34724
  ident: b1365
  article-title: Gold nanocluster-mediated efficient delivery of Cas9 protein through pH-induced assembly-disassembly for inactivation of virus oncogenes
  publication-title: Acs Appl. Mater. Inter.
– volume: 12
  start-page: 1313
  year: 2020
  end-page: 1321
  ident: b0405
  article-title: Knocking Out SST Gene of BGC823 Gastric Cancer Cell by CRISPR/Cas9 Enhances Migration, Invasion and Expression of SEMA5A and KLF2
  publication-title: Cancer Manag. Res.
– volume: 11
  start-page: 46585
  year: 2019
  end-page: 46590
  ident: b1390
  article-title: Cell-selective messenger RNA delivery and CRISPR/Cas9 genome editing by modulating the interface of phenylboronic acid-derived lipid nanoparticles and cellular surface sialic acid
  publication-title: Acs Appl. Mater. Inter.
– volume: 19
  start-page: 902
  year: 2020
  ident: b0210
  article-title: RAS-targeted therapies: is the undruggable drugged? (vol 19, pg 533, 2020)
  publication-title: Nat. Rev. Drug Discov.
– volume: 10
  year: 2020
  ident: b0340
  article-title: CRISPR/Cas9-mediated OC-2 editing inhibits the tumor growth and angiogenesis of ovarian cancer
  publication-title: Front. Oncol.
– volume: 23
  start-page: 1398
  year: 2016
  end-page: 1403
  ident: b0615
  article-title: Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect
  publication-title: Drug Deliv.
– volume: 10
  start-page: 412
  year: 2020
  end-page: 426
  ident: b0050
  article-title: Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems
  publication-title: Clin. Transl. Med.
– volume: 10
  year: 2020
  ident: b0265
  article-title: CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism
  publication-title: Sci Rep-Uk
– volume: 142
  start-page: 1715
  year: 2020
  end-page: 1720
  ident: b1305
  article-title: Cell-type-specific CRISPR/Cas9 delivery by biomimetic metal organic frameworks
  publication-title: J. Am. Chem. Soc.
– volume: 450
  start-page: 1422
  year: 2014
  end-page: 1426
  ident: b0450
  article-title: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9
  publication-title: Biochem. Bioph. Res. Co
– volume: 65
  start-page: 703
  year: 2013
  end-page: 718
  ident: b0790
  article-title: Quantum dots as a platform for nanoparticle drug delivery vehicle design
  publication-title: Adv. Drug Deliver Rev.
– volume: 57
  start-page: 10268
  year: 2018
  end-page: 10272
  ident: b0890
  article-title: Enhanced cytosolic delivery and release of CRISPR/Cas9 by black phosphorus nanosheets for genome editing
  publication-title: Angew. Chem. Int. Ed.
– volume: 10
  start-page: 161
  year: 2015
  end-page: 174
  ident: b1035
  article-title: Nanobody-based cancer therapy of solid tumors
  publication-title: Nanomedicine-Uk
– volume: 17
  start-page: 300
  year: 2020
  end-page: 312
  ident: b0220
  article-title: Immunotherapeutic approaches for small-cell lung cancer
  publication-title: Nat. Rev. Clin. Oncol.
– volume: 103
  start-page: 598
  year: 2018
  end-page: 613
  ident: b0590
  article-title: Nanostructured lipid carriers for site-specific drug delivery
  publication-title: Biomed. Pharmacother.
– volume: 10
  year: 2020
  ident: b0375
  article-title: PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells
  publication-title: Sci. Rep.-Uk
– volume: 8
  start-page: 94666
  year: 2017
  end-page: 94680
  ident: b0325
  article-title: Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells
  publication-title: Oncotarget
– volume: 171
  start-page: 207
  year: 2018
  end-page: 218
  ident: b0800
  article-title: Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
  publication-title: Biomaterials
– volume: 45
  start-page: 2287
  year: 2007
  end-page: 2303
  ident: b0880
  article-title: Dendritic polyamine architectures with lipophilic shells as nanocompartments for polar guest molecules: a comparative study of their transport behavior
  publication-title: J. Polym. Sci. Pol. Chem.
– volume: 6
  start-page: 3975
  year: 2020
  end-page: 3983
  ident: b0925
  article-title: Effect of poly(ethylene glycol) (PEG) surface density on the fate and antitumor efficacy of redox-sensitive hybrid nanoparticles
  publication-title: ACS Biomater. Sci. Eng.
– volume: 14
  start-page: 974-+
  year: 2019
  ident: b1395
  article-title: A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing
  publication-title: Nat. Nanotechnol.
– volume: 529
  start-page: 321
  year: 2020
  end-page: 327
  ident: b0280
  article-title: Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show inhibition of aggressive characteristics in breast cancer cells
  publication-title: Biochem. Bioph. Res. Co.
– volume: 18
  start-page: 175
  year: 2019
  end-page: 196
  ident: b1455
  article-title: Delivery technologies for cancer immunotherapy
  publication-title: Nat. Rev. Drug Discov.
– volume: 11
  year: 2019
  ident: b0360
  article-title: CRISPR-Cas9 knockdown and induced expression of CD133 reveal essential roles in melanoma invasion and metastasis
  publication-title: Cancers
– year: 2021
  ident: b0480
  article-title: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
  publication-title: New Engl. J. Med.
– year: 2020
  ident: b1030
  article-title: Recent advances in HER2-targeted delivery for cancer therapy
  publication-title: Drug Discov. Today
– volume: 27
  start-page: 2091
  year: 2019
  end-page: 2099
  ident: b0950
  article-title: Systemic delivery of CRISPR/Cas9 targeting HPV oncogenes is effective at eliminating established tumors
  publication-title: Mol. Ther.
– volume: 43
  start-page: 58
  year: 2020
  end-page: 79
  ident: b1465
  article-title: Nanotechnology in the arena of cancer immunotherapy
  publication-title: Arch. Pharm. Res.
– volume: 6
  year: 2020
  ident: b1405
  article-title: Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects
  publication-title: Sci. Adv.
– volume: 147
  start-page: 2902
  year: 2020
  end-page: 2913
  ident: b0370
  article-title: The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells
  publication-title: Int. J. Cancer
– volume: 84
  start-page: 7413
  year: 1987
  end-page: 7417
  ident: b0635
  article-title: Lipofection - a highly efficient, lipid-mediated DNA-transfection procedure
  publication-title: P. Natl. Acad. Sci. USA
– volume: 5
  start-page: 209
  year: 2011
  end-page: 216
  ident: b0475
  article-title: Uniformity of drug payload and its effect on stability of solid lipid nanoparticles containing an ester prodrug
  publication-title: ACS Nano
– volume: 28
  start-page: 172
  year: 2010
  end-page: U118
  ident: b1310
  article-title: Rational design of cationic lipids for siRNA delivery
  publication-title: Nat. Biotechnol.
– volume: 21
  start-page: 87
  year: 2014
  end-page: 100
  ident: b0650
  article-title: Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations
  publication-title: Drug Deliv.
– volume: 18
  start-page: 491
  year: 2018
  end-page: 505
  ident: b0780
  article-title: Functional carbon quantum dots: a versatile platform for chemosensing and biosensing
  publication-title: Chem. Rec.
– volume: 66
  start-page: 2
  year: 2014
  end-page: 25
  ident: b1000
  article-title: Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
  publication-title: Adv. Drug Deliver. Rev.
– volume: 3
  start-page: 446
  year: 2018
  end-page: 447
  ident: b0575
  article-title: Exploring cutting-edge hydrogel technologies and their biomedical applications
  publication-title: Bioact. Mater.
– volume: 13
  start-page: 82-+
  year: 2018
  ident: b1140
  article-title: Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression
  publication-title: Nat. Nanotechnol.
– volume: 190
  start-page: 1401
  year: 2008
  end-page: 1412
  ident: b0110
  article-title: Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus
  publication-title: J. Bacteriol.
– volume: 11
  start-page: 923
  year: 2020
  end-page: 936
  ident: b0760
  article-title: Surface chemistry of gold nanoparticles for health-related applications
  publication-title: Chem. Sci.
– volume: 6
  year: 2020
  ident: b0845
  article-title: CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
  publication-title: Sci. Adv.
– volume: 12
  start-page: 6830
  year: 2018
  end-page: 6842
  ident: b1145
  article-title: Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems
  publication-title: ACS Nano
– volume: 232
  year: 2019
  ident: b0155
  article-title: CRISPR-Cas9 system: a new-fangled dawn in gene editing
  publication-title: Life Sci.
– volume: 10
  year: 2019
  ident: b0390
  article-title: Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling
  publication-title: Cell Death Dis.
– volume: 10
  start-page: 358
  year: 2020
  end-page: 373
  ident: b1480
  article-title: Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity
  publication-title: Acta Pharmacol. Sin. B
– volume: 18
  start-page: 1507
  year: 2017
  end-page: 1525
  ident: b0665
  article-title: Porous inorganic drug delivery systems-a review
  publication-title: Aaps Pharmscitech
– volume: 35
  start-page: 4835
  year: 2014
  end-page: 4847
  ident: b1200
  article-title: Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
  publication-title: Biomaterials
– volume: 12
  year: 2020
  ident: b0055
  article-title: Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics
  publication-title: Wires Nanomed. Nanobi.
– volume: 15
  year: 2020
  ident: b1110
  article-title: Anti-EPCAM APTamer (Syl3c)-functionalized liposome for targeted delivery of doxorubicin. In vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma
  publication-title: Nanoscale Res. Lett.
– volume: 185
  start-page: 22
  year: 2014
  end-page: 36
  ident: b0645
  article-title: Nano-niosomes as nanoscale drug delivery systems: an illustrated review
  publication-title: J. Control. Release
– volume: 13
  start-page: 187
  year: 2019
  end-page: 202
  ident: b1285
  article-title: Super-resolution imaging of proton sponge-triggered rupture of endosomes and cytosolic release of small interfering RNA
  publication-title: ACS Nano
– volume: 43
  start-page: 1565
  year: 2002
  end-page: 1575
  ident: b0090
  article-title: Identification of genes that are associated with DNA repeats in prokaryotes
  publication-title: Mol. Microbiol.
– year: 2021
  ident: b0765
  article-title: Intraoperative assessment and photothermal ablation of the tumor margins using gold nanoparticles
  publication-title: Adv. Sci.
– volume: 18
  start-page: 74
  year: 2018
  end-page: 86
  ident: b1165
  article-title: Tumor-targeting peptides: ligands for molecular imaging and therapy
  publication-title: Anti-Cancer Agent Me
– volume: 266
  start-page: 8
  year: 2017
  end-page: 16
  ident: b1060
  article-title: Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
  publication-title: J. Control. Release
– volume: 12
  year: 2020
  ident: b0625
  article-title: Continuous-flow production of liposomes with a millireactor under varying fluidic conditions
  publication-title: Pharmaceutics
– volume: 322
  start-page: 236
  year: 2020
  end-page: 247
  ident: b0850
  article-title: Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy
  publication-title: J. Control. Release
– volume: 26
  start-page: 2443
  year: 2018
  end-page: 2455
  ident: b0860
  article-title: Nanoparticles based on poly (beta-Amino Ester) and HPV16-targeting CRISPR/shRNA as potential drugs for HPV16-related cervical malignancy
  publication-title: Mol. Ther.
– volume: 339
  start-page: 819
  year: 2013
  end-page: 823
  ident: b0035
  article-title: Multiplex Genome Engineering Using CRISPR/Cas Systems
  publication-title: Science
– year: 2019
  ident: b1435
  article-title: A photolabile semiconducting polymer nanotransducer for near-infrared regulation of CRISPR/Cas9 gene editing
  publication-title: Angew. Chem. Int. Ed.
– volume: 96
  start-page: 13
  year: 2019
  end-page: 21
  ident: b0015
  article-title: Advancements in CRISPR/Cas9 technology-Focusing on cancer therapeutics and beyond
  publication-title: Semin. Cell Dev. Biol.
– volume: 109
  start-page: 12426
  year: 2012
  end-page: 12431
  ident: b1250
  article-title: Laminin receptor specific therapeutic gold nanoparticles ((AuNP)-Au-198-EGCg) show efficacy in treating prostate cancer
  publication-title: P. Natl. Acad. Sci. USA
– volume: 21
  year: 2019
  ident: b0065
  article-title: Delivery of CRISPR/Cas9 for therapeutic genome editing
  publication-title: J. Gene Med.
– volume: 4
  start-page: 726
  year: 2019
  end-page: 737
  ident: b0070
  article-title: Engineered materials for in vivo delivery of genome-editing machinery
  publication-title: Nat. Rev. Mater.
– volume: 6
  year: 2019
  ident: b0725
  article-title: Structural engineering of low-dimensional metal-organic frameworks: synthesis, properties, and applications
  publication-title: Adv. Sci.
– volume: 12
  start-page: 8325
  year: 2017
  end-page: 8336
  ident: b0605
  article-title: Solid lipid nanoparticles for thermoresponsive targeting: evidence from spectrophotometry, electrochemical, and cytotoxicity studies
  publication-title: Int. J. Nanomed.
– volume: 9
  start-page: 497
  year: 2012
  end-page: 508
  ident: b0600
  article-title: Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery
  publication-title: Expert Opin. Drug Del.
– volume: 10
  start-page: 524
  year: 2014
  end-page: 535
  ident: b0820
  article-title: Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer
  publication-title: Small
– volume: 115
  start-page: 4903
  year: 2018
  end-page: 4908
  ident: b1330
  article-title: Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide
  publication-title: P. Natl. Acad. Sci. USA
– volume: 10
  start-page: 5137
  year: 2020
  end-page: 5153
  ident: b0215
  article-title: Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression
  publication-title: Theranostics
– volume: 58
  start-page: 12076
  year: 2019
  end-page: 12080
  ident: b0750
  article-title: Correlating anticancer drug delivery efficiency with vascular permeability of renal clearable versus non-renal clearable nanocarriers
  publication-title: Angew. Chem. Int. Ed.
– volume: 5
  start-page: 92
  year: 2020
  end-page: 101
  ident: b1180
  article-title: Peptide-based targeting of immunosuppressive cells in cancer
  publication-title: Bioact. Mater.
– volume: 66
  start-page: 184
  year: 2002
  end-page: 199
  ident: b1170
  article-title: Therapeutic cancer targeting peptides
  publication-title: Biopolymers
– volume: 11
  year: 2020
  ident: b0975
  article-title: Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
  publication-title: Nat. Commun.
– volume: 34
  start-page: 257
  year: 2018
  end-page: 263
  ident: b0410
  article-title: Disruption of the Tff1 gene in mice using CRISPR/Cas9 promotes body weight reduction and gastric tumorigenesis
  publication-title: Lab Anim. Res.
– volume: 98
  start-page: 734
  year: 2018
  end-page: 744
  ident: b0295
  article-title: Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma
  publication-title: Lab. Invest.
– volume: 10
  year: 2019
  ident: b0350
  article-title: Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment
  publication-title: Front. Pharmacol.
– volume: 37
  start-page: 4626
  year: 2018
  end-page: 4632
  ident: b0445
  article-title: Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma
  publication-title: Oncogene
– volume: 90
  start-page: 2331
  year: 2018
  end-page: 2346
  ident: b0545
  article-title: Perspectives of dendrimer-based nanoparticles in cancer therapy
  publication-title: An. Acad. Bras. Cienc
– volume: 5
  start-page: 1877
  year: 2011
  end-page: 1887
  ident: b1295
  article-title: Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing
  publication-title: ACS Nano
– volume: 337
  start-page: 816
  year: 2012
  end-page: 821
  ident: b0135
  article-title: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity
  publication-title: Science
– volume: 22
  year: 2017
  ident: b0500
  article-title: Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy
  publication-title: Molecules
– volume: 171
  start-page: 349
  year: 2013
  end-page: 357
  ident: b0620
  article-title: Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA
  publication-title: J. Control. Release
– volume: 26
  start-page: 290
  year: 2020
  end-page: 300
  ident: b0195
  article-title: Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer
  publication-title: Clin. Cancer Res.
– volume: 185
  year: 2018
  ident: b0785
  article-title: Surface modification and chemical functionalization of carbon dots: a review
  publication-title: Microchim. Acta
– volume: 11
  start-page: 313
  year: 2015
  end-page: 327
  ident: b0695
  article-title: Mesoporous silica nanoparticles in drug delivery and biomedical applications
  publication-title: Nanomed.-Nanotechnol.
– volume: 9
  year: 2018
  ident: b0990
  article-title: Progress and challenges towards targeted delivery of cancer therapeutics
  publication-title: Nat. Commun.
– volume: 263
  year: 2020
  ident: b0130
  article-title: CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions
  publication-title: Life Sci.
– volume: 28
  start-page: 146
  year: 2018
  end-page: 157
  ident: b1315
  article-title: Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
  publication-title: Nucleic Acid Ther.
– volume: 54
  start-page: 12029
  year: 2015
  end-page: 12033
  ident: b0900
  article-title: Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing
  publication-title: Angew. Chem. Int. Ed.
– volume: 33
  year: 2020
  ident: b0250
  article-title: Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
  publication-title: Cell Rep
– volume: 67
  start-page: 657-+
  year: 2003
  ident: b0005
  article-title: RNA interference: Biology, mechanism, and applications
  publication-title: Microbiol. Mol. Biol. R
– volume: 7
  year: 2020
  ident: b1335
  article-title: Appropriate delivery of the CRISPR/Cas9 system through the nonlysosomal route: application for therapeutic gene editing
  publication-title: Adv. Sci.
– volume: 12
  start-page: 3117
  year: 2018
  end-page: 3145
  ident: b0515
  article-title: Current development of biodegradable polymeric materials for biomedical applications
  publication-title: Drug Des. Dev. Ther.
– volume: 18
  start-page: 154
  year: 2018
  end-page: 164
  ident: b0720
  article-title: Metal-organic frameworks (MOFs) as functional supramolecular architectures for anion recognition and sensing
  publication-title: Chem. Rec.
– volume: 14
  start-page: 8012
  year: 2020
  end-page: 8023
  ident: b1290
  article-title: Lysosomal proton buffering of poly(ethylenimine) measured in situ by fluorescent pH-sensor microcapsules
  publication-title: ACS Nano
– volume: 58
  start-page: 924
  year: 2018
  end-page: 941
  ident: b1245
  article-title: Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review
  publication-title: Crit. Rev. Food Sci.
– volume: 37
  start-page: 410
  year: 2019
  end-page: 421
  ident: b0160
  article-title: The application of the CRISPR-Cas9 genome editing machinery in food and agricultural science: Current status, future perspectives, and associated challenges
  publication-title: Biotechnol. Adv.
– volume: 16
  start-page: 497
  year: 2019
  end-page: 506
  ident: b0830
  article-title: Deep eutectic solvents comprising active pharmaceutical ingredients in the development of drug delivery systems
  publication-title: Expert. Opin. Drug Deliv.
– volume: 7
  start-page: 655
  year: 2015
  end-page: 677
  ident: b0940
  article-title: Anti-PEG immunity: emergence, characteristics, and unaddressed questions
  publication-title: Wires Nanomed. Nanobi.
– volume: 341
  start-page: 833
  year: 2013
  end-page: 836
  ident: b0025
  article-title: The CRISPR Craze
  publication-title: Science
– volume: 57
  start-page: 1491
  year: 2018
  end-page: 1496
  ident: b1440
  article-title: Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy
  publication-title: Angew. Chem. Int. Ed.
– volume: 12
  year: 2017
  ident: b0460
  article-title: CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle
  publication-title: PLoS ONE
– volume: 117
  start-page: 513
  year: 2020
  end-page: 521
  ident: b0230
  article-title: CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer
  publication-title: P. Natl. Acad. Sci. USA
– volume: 9
  start-page: 988
  year: 2019
  end-page: 998
  ident: b0330
  article-title: Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening
  publication-title: Am. J. Cancer Res.
– volume: 20
  year: 2018
  ident: b0980
  article-title: Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics
  publication-title: AAPS J.
– volume: 55
  start-page: 106
  year: 2019
  end-page: 119
  ident: b0045
  article-title: CRISPR/Cas9 for cancer research and therapy
  publication-title: Semin. Cancer Biol.
– volume: 353
  start-page: 399
  year: 2016
  end-page: 403
  ident: b1485
  article-title: Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
  publication-title: Science
– volume: 94
  start-page: 2135
  year: 2005
  end-page: 2146
  ident: b1230
  article-title: Folate receptor-mediated drug targeting: from therapeutics to diagnostics
  publication-title: J. Pharm. Sci.-Us
– volume: 568
  start-page: 511-+
  year: 2019
  ident: b0465
  article-title: Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
  publication-title: Nature
– volume: 11
  year: 2018
  ident: b0335
  article-title: Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing
  publication-title: J. Ovarian Res.
– volume: 19
  start-page: 486
  year: 2020
  end-page: 487
  ident: b0985
  article-title: A nanoparticle’s pathway into tumours
  publication-title: Nat. Mater.
– volume: 96
  start-page: 1314
  year: 2020
  end-page: 1320
  ident: b0355
  article-title: CRISPR/Cas9-mediated knockout of SIRT6 imparts remarkable antiproliferative response in human melanoma cellsin vitroandin vivo
  publication-title: Photochem. Photobiol.
– volume: 240
  year: 2020
  ident: b0675
  article-title: Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis
  publication-title: Biomaterials
– volume: 6
  start-page: 2174
  year: 2012
  end-page: 2188
  ident: b0715
  article-title: Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers
  publication-title: ACS Nano
– volume: 371
  start-page: 1
  year: 2018
  end-page: 19
  ident: b1025
  article-title: Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics
  publication-title: Exp. Cell Res.
– volume: 134
  start-page: 65
  year: 2018
  end-page: 78
  ident: b1070
  article-title: Aptamer-based targeted therapy
  publication-title: Adv Drug Deliver Rev
– volume: 11
  year: 2020
  ident: b0180
  article-title: CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
  publication-title: Front. Immunol.
– volume: 33
  start-page: 334
  year: 2020
  end-page: 344
  ident: b0365
  article-title: A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma
  publication-title: Pigm. Cell Melanoma R
– volume: 9
  start-page: 13976
  year: 2017
  end-page: 13987
  ident: b0690
  article-title: A versatile carbonic anhydrase IX targeting ligand-functionalized porous silicon nanoplatform for dual hypoxia cancer therapy and imaging
  publication-title: Acs Appl. Mater. Inter.
– volume: 8
  start-page: 9375
  year: 2017
  end-page: 9387
  ident: b1130
  article-title: Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome
  publication-title: Oncotarget
– volume: 44
  start-page: 4023
  year: 2015
  end-page: 4071
  ident: b0865
  article-title: Bioapplications of hyperbranched polymers
  publication-title: Chem. Soc. Rev.
– volume: 27
  start-page: 1
  year: 2019
  end-page: 11
  ident: b1190
  article-title: RGD peptide-based non-viral gene delivery vectors targeting integrin alpha(v)beta(3) for cancer therapy
  publication-title: J. Drug Target.
– volume: 10
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0350
  article-title: Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2019.01456
– volume: 44
  start-page: 4023
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0865
  article-title: Bioapplications of hyperbranched polymers
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/C4CS00229F
– volume: 171
  start-page: 349
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0620
  article-title: Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2013.04.018
– volume: 66
  start-page: 2
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b1000
  article-title: Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
  publication-title: Adv. Drug Deliver. Rev.
  doi: 10.1016/j.addr.2013.11.009
– volume: 8
  start-page: 47020
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0320
  article-title: Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16638
– volume: 40
  start-page: 177
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b0315
  article-title: Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth
  publication-title: Oncogene
  doi: 10.1038/s41388-020-01523-5
– volume: 43
  start-page: 58
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1465
  article-title: Nanotechnology in the arena of cancer immunotherapy
  publication-title: Arch. Pharm. Res.
  doi: 10.1007/s12272-020-01207-4
– volume: 115
  start-page: 4903
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1330
  article-title: Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide
  publication-title: P. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1712963115
– volume: 28
  start-page: 146
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1315
  article-title: Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
  publication-title: Nucleic Acid Ther.
  doi: 10.1089/nat.2018.0721
– year: 2019
  ident: 10.1016/j.addr.2021.113891_b1435
  article-title: A photolabile semiconducting polymer nanotransducer for near-infrared regulation of CRISPR/Cas9 gene editing
  publication-title: Angew. Chem. Int. Ed.
– volume: 65
  start-page: 703
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0790
  article-title: Quantum dots as a platform for nanoparticle drug delivery vehicle design
  publication-title: Adv. Drug Deliver Rev.
  doi: 10.1016/j.addr.2012.09.036
– volume: 32
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1040
  article-title: Cancer-targeting nanoparticles for combinatorial nucleic acid delivery
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201901081
– volume: 10
  start-page: 5137
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0215
  article-title: Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression
  publication-title: Theranostics
  doi: 10.7150/thno.42325
– volume: 13
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1280
  article-title: Insight into cellular uptake and intracellular trafficking of nanoparticles
  publication-title: Nanoscale Res. Lett.
  doi: 10.1186/s11671-018-2728-6
– volume: 8
  start-page: 33300
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0240
  article-title: IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16350
– volume: 116
  start-page: 18295
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1340
  article-title: Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel
  publication-title: P Natl Acad Sci USA
  doi: 10.1073/pnas.1904697116
– volume: 58
  start-page: 12076
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0750
  article-title: Correlating anticancer drug delivery efficiency with vascular permeability of renal clearable versus non-renal clearable nanocarriers
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201905738
– volume: 249
  start-page: 505
  year: 1990
  ident: 10.1016/j.addr.2021.113891_b1075
  article-title: Systematic evolution of ligands by exponential enrichment - rna ligands to bacteriophage-T4 DNA-polymerase
  publication-title: Science
  doi: 10.1126/science.2200121
– volume: 27
  start-page: 1461
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0680
  article-title: A sustained dual drug delivery system for proliferative vitreoretinopathy
  publication-title: Drug Deliv.
  doi: 10.1080/10717544.2020.1833382
– volume: 16
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b0080
  article-title: Inorganic porous nanoparticles for drug delivery in antitumoral therapy
  publication-title: Biotechnol. J.
  doi: 10.1002/biot.202000150
– volume: 10
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0520
  article-title: Micelles structure development as a strategy to improve smart cancer therapy
  publication-title: Cancers
  doi: 10.3390/cancers10070238
– volume: 86
  start-page: 595
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0610
  article-title: Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2016.12.041
– volume: 18
  start-page: 491
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0780
  article-title: Functional carbon quantum dots: a versatile platform for chemosensing and biosensing
  publication-title: Chem. Rec.
  doi: 10.1002/tcr.201700055
– volume: 9
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1125
  article-title: Selective targeting of the hedgehog signaling pathway by PBM nanoparticles in docetaxel-resistant prostate cancer
  publication-title: Cells-Basel
– volume: 185
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0785
  article-title: Surface modification and chemical functionalization of carbon dots: a review
  publication-title: Microchim. Acta
  doi: 10.1007/s00604-018-2953-9
– volume: 31
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1385
  article-title: Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201902575
– volume: 20
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0980
  article-title: Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics
  publication-title: AAPS J.
  doi: 10.1208/s12248-018-0267-9
– volume: 146
  start-page: 1509
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0285
  article-title: Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively
  publication-title: J. Cancer Res. Clin.
  doi: 10.1007/s00432-020-03207-9
– volume: 463
  start-page: 568
  year: 2010
  ident: 10.1016/j.addr.2021.113891_b0120
  article-title: Self versus non-self discrimination during CRISPR RNA-directed immunity
  publication-title: Nature
  doi: 10.1038/nature08703
– volume: 34
  start-page: 257
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0410
  article-title: Disruption of the Tff1 gene in mice using CRISPR/Cas9 promotes body weight reduction and gastric tumorigenesis
  publication-title: Lab Anim. Res.
  doi: 10.5625/lar.2018.34.4.257
– volume: 4
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0895
  article-title: Genome editing for cancer therapy: delivery of Cas9 Protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier
  publication-title: Adv. Sci.
  doi: 10.1002/advs.201700175
– volume: 9
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1460
  article-title: Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology
  publication-title: Cells-Basel
– volume: 142
  start-page: 1715
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1305
  article-title: Cell-type-specific CRISPR/Cas9 delivery by biomimetic metal organic frameworks
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.9b11638
– volume: 141
  start-page: 19032
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1410
  article-title: A self-assembled platform based on branched DNA for sgRNA/Cas9/antisense delivery
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.9b09043
– volume: 450
  start-page: 1422
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0450
  article-title: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9
  publication-title: Biochem. Bioph. Res. Co
  doi: 10.1016/j.bbrc.2014.07.014
– volume: 12
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0460
  article-title: CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0182373
– volume: 14
  start-page: 974-+
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1395
  article-title: A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-019-0539-2
– volume: 42
  start-page: 419
  year: 2003
  ident: 10.1016/j.addr.2021.113891_b0935
  article-title: Pharmacokinetics of pegylated liposomal doxorubicin - review of animal and human studies
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-200342050-00002
– volume: 52
  start-page: 1750
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1270
  article-title: Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors
  publication-title: Accounts Chem. Res.
  doi: 10.1021/acs.accounts.9b00177
– volume: 51
  start-page: 1879
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0430
  article-title: Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells
  publication-title: Cell. Physiol. Biochem.
  doi: 10.1159/000495714
– volume: 5
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0275
  article-title: CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells
  publication-title: Bioeng. Transl. Med.
  doi: 10.1002/btm2.10152
– volume: 466
  start-page: 1441
  year: 2010
  ident: 10.1016/j.addr.2021.113891_b0540
  article-title: Unique structure and property of dendrimers in biomedical applications INTRODUCTION
  publication-title: P. Roy. Soc. a-Math. Phy.
– volume: 291
  start-page: 90
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1095
  article-title: Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2018.10.018
– volume: 39
  start-page: 795
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0455
  article-title: Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells
  publication-title: Oncol. Rep.
– volume: 10
  start-page: 524
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0820
  article-title: Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer
  publication-title: Small
  doi: 10.1002/smll.201301992
– volume: 83
  start-page: 3080
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0270
  article-title: CRISPR-Cas9 genome-wide knockout screen identifies mechanism of selective activity of dehydrofalcarinol in mesenchymal stem-like triple-negative breast cancer cells
  publication-title: J. Nat. Prod.
  doi: 10.1021/acs.jnatprod.0c00642
– year: 2021
  ident: 10.1016/j.addr.2021.113891_b0480
  article-title: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
  publication-title: New Engl. J. Med.
  doi: 10.1056/NEJMoa2107454
– volume: 20
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0655
  article-title: Rapid microfluidic preparation of niosomes for targeted drug delivery
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20194696
– volume: 24
  start-page: 955
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0165
  article-title: CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
  publication-title: Drug Discov. Today
  doi: 10.1016/j.drudis.2019.02.011
– volume: 23
  start-page: 3367
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0705
  article-title: Advances in functionalized mesoporous silica nanoparticles for tumor targeted drug delivery and theranostics
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612822666161025153619
– year: 2020
  ident: 10.1016/j.addr.2021.113891_b1375
  article-title: Spatiotemporal delivery of CRISPR/Cas9 genome editing machinery using stimuli-responsive vehicles
  publication-title: Angew. Chem. Int. Ed.
– volume: 5
  start-page: 92
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1180
  article-title: Peptide-based targeting of immunosuppressive cells in cancer
  publication-title: Bioact. Mater.
– volume: 337
  start-page: 816
  year: 2012
  ident: 10.1016/j.addr.2021.113891_b0135
  article-title: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity
  publication-title: Science
  doi: 10.1126/science.1225829
– volume: 145
  start-page: 192
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0425
  article-title: Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.32072
– volume: 232
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0155
  article-title: CRISPR-Cas9 system: a new-fangled dawn in gene editing
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2019.116636
– volume: 94
  start-page: 2135
  year: 2005
  ident: 10.1016/j.addr.2021.113891_b1230
  article-title: Folate receptor-mediated drug targeting: from therapeutics to diagnostics
  publication-title: J. Pharm. Sci.-Us
  doi: 10.1002/jps.20457
– volume: 6
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0725
  article-title: Structural engineering of low-dimensional metal-organic frameworks: synthesis, properties, and applications
  publication-title: Adv. Sci.
  doi: 10.1002/advs.201802373
– volume: 18
  start-page: 74
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1165
  article-title: Tumor-targeting peptides: ligands for molecular imaging and therapy
  publication-title: Anti-Cancer Agent Me
  doi: 10.2174/1871520617666170419143459
– volume: 11
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0140
  article-title: A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17962-3
– volume: 12
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0055
  article-title: Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics
  publication-title: Wires Nanomed. Nanobi.
  doi: 10.1002/wnan.1609
– volume: 37
  start-page: 4626
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0445
  article-title: Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0292-2
– volume: 6
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1405
  article-title: Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abb4005
– volume: 18
  start-page: 649
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0570
  article-title: Stimuli-responsive polymersomes for biomedical applications
  publication-title: Biomacromolecules
  doi: 10.1021/acs.biomac.6b01704
– volume: 3
  start-page: 446
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0575
  article-title: Exploring cutting-edge hydrogel technologies and their biomedical applications
  publication-title: Bioact. Mater.
– volume: 529
  start-page: 321
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0280
  article-title: Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show inhibition of aggressive characteristics in breast cancer cells
  publication-title: Biochem. Bioph. Res. Co.
  doi: 10.1016/j.bbrc.2020.05.172
– volume: 37
  start-page: 1518
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1080
  article-title: Anti-MUC1 aptamer: a potential opportunity for cancer treatment
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21462
– volume: 142
  start-page: 40
  year: 2010
  ident: 10.1016/j.addr.2021.113891_b0565
  article-title: pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2009.09.023
– volume: 9
  start-page: 497
  year: 2012
  ident: 10.1016/j.addr.2021.113891_b0600
  article-title: Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery
  publication-title: Expert Opin. Drug Del.
  doi: 10.1517/17425247.2012.673278
– volume: 263
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0130
  article-title: CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2020.118525
– volume: 10
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0345
  article-title: Knockout ofEGFL6by CRISPR/Cas9 mediated inhibition of tumor angiogenesis in ovarian cancer
  publication-title: Front. Oncol.
– volume: 9
  start-page: 13976
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0690
  article-title: A versatile carbonic anhydrase IX targeting ligand-functionalized porous silicon nanoplatform for dual hypoxia cancer therapy and imaging
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.7b04038
– volume: 4
  start-page: 726
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0070
  article-title: Engineered materials for in vivo delivery of genome-editing machinery
  publication-title: Nat. Rev. Mater.
  doi: 10.1038/s41578-019-0145-9
– volume: 8
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1470
  article-title: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00561
– volume: 27
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1215
  article-title: Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.201703036
– volume: 70
  start-page: 1810
  year: 1992
  ident: 10.1016/j.addr.2021.113891_b0020
  article-title: Gene-therapy of cancer through restoration of tumor-suppressor functions
  publication-title: Cancer
  doi: 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3
– volume: 6
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0960
  article-title: Multistage delivery nanoparticle facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo
  publication-title: Adv. Sci.
– volume: 33
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0250
  article-title: Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2020.108444
– volume: 447
  start-page: 48
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0030
  article-title: CRISPR-Cas9 for cancer therapy: Opportunities and challenges
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.01.017
– volume: 190
  start-page: 1401
  year: 2008
  ident: 10.1016/j.addr.2021.113891_b0110
  article-title: Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus
  publication-title: J. Bacteriol.
  doi: 10.1128/JB.01415-07
– volume: 12
  start-page: 1313
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0405
  article-title: Knocking Out SST Gene of BGC823 Gastric Cancer Cell by CRISPR/Cas9 Enhances Migration, Invasion and Expression of SEMA5A and KLF2
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S236374
– volume: 29
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0510
  article-title: Metal-organic framework (MOF)-based drug/cargo delivery and cancer therapy
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201606134
– volume: 32
  start-page: 4058
  year: 2011
  ident: 10.1016/j.addr.2021.113891_b0535
  article-title: Formulation of Docetaxel by folic acid-conjugated D-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2011.02.022
– volume: 11
  start-page: 95
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1195
  article-title: Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice
  publication-title: ACS Nano
  doi: 10.1021/acsnano.6b04261
– volume: 10
  start-page: 4557
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1380
  article-title: Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
  publication-title: Theranostics
  doi: 10.7150/thno.38069
– volume: 13
  start-page: 4727
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0485
  article-title: Recent advances in “smart” delivery systems for extended drug release in cancer therapy
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S168053
– volume: 367
  start-page: 525-+
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0470
  article-title: Neoadjuvant checkpoint blockade for cancer immunotherapy
  publication-title: Science
  doi: 10.1126/science.aax0182
– volume: 141
  start-page: 9937
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1400
  article-title: Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.9b03457
– volume: 20
  start-page: 555
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0175
  article-title: A compendium of mutational cancer driver genes
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-020-0290-x
– volume: 23
  start-page: 1398
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0615
  article-title: Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect
  publication-title: Drug Deliv.
  doi: 10.3109/10717544.2015.1055619
– volume: 15
  start-page: 497
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0505
  article-title: Nanotechnology as a promising strategy for anticancer drug delivery
  publication-title: Curr. Drug Deliv.
  doi: 10.2174/1567201814666170516114411
– volume: 28
  start-page: 172
  year: 2010
  ident: 10.1016/j.addr.2021.113891_b1310
  article-title: Rational design of cationic lipids for siRNA delivery
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1602
– volume: 38
  start-page: 6399
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0235
  article-title: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0887-2
– volume: 9
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0990
  article-title: Progress and challenges towards targeted delivery of cancer therapeutics
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-03705-y
– volume: 10
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0265
  article-title: CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism
  publication-title: Sci Rep-Uk
– volume: 36
  start-page: 1211
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0310
  article-title: Knockdown of EPHA1 by CRISPR/CAS9 promotes adhesion and motility of HRT18 colorectal carcinoma cells
  publication-title: Anticancer Res.
– volume: 16
  start-page: 6823
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0970
  article-title: Ultrasensitive pH triggered charge/size dual-rebound gene delivery system
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.6b02536
– volume: 145
  start-page: 182
  year: 2010
  ident: 10.1016/j.addr.2021.113891_b1325
  article-title: Endocytosis of nanomedicines
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2010.01.036
– volume: 12
  start-page: 6830
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1145
  article-title: Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b02053
– volume: 12
  start-page: 8325
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0605
  article-title: Solid lipid nanoparticles for thermoresponsive targeting: evidence from spectrophotometry, electrochemical, and cytotoxicity studies
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S147506
– volume: 98
  start-page: 734
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0295
  article-title: Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma
  publication-title: Lab. Invest.
  doi: 10.1038/s41374-018-0027-6
– volume: 10
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0375
  article-title: PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells
  publication-title: Sci. Rep.-Uk
– volume: 19
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0420
  article-title: Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells
  publication-title: Bmc Cancer
  doi: 10.1186/s12885-019-5455-1
– volume: 30
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0685
  article-title: Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy
  publication-title: Adv. Mater.
– volume: 9
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1050
  article-title: Adult stem cell-derived extracellular vesicles in cancer treatment: opportunities and challenges
  publication-title: Cells-Basel
– volume: 37
  start-page: 789
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0440
  article-title: Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma
  publication-title: J. Orthop. Res.
  doi: 10.1002/jor.24227
– volume: 9
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1185
  article-title: Exploring the role of RGD-recognizing integrins in cancer
  publication-title: Cancers
  doi: 10.3390/cancers9090116
– volume: 12
  start-page: 57362
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0290
  article-title: Co-delivery of sorafenib and CRISPR/Cas9 based on targeted core-shell hollow mesoporous organosilica nanoparticles for synergistic HCC therapy
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.0c17660
– volume: 510
  start-page: 235-+
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0150
  article-title: Targeted genome editing in human repopulating haematopoietic stem cells
  publication-title: Nature
  doi: 10.1038/nature13420
– volume: 68
  start-page: 165
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0490
  article-title: Drug delivery systems improving chemical and physical properties of anticancer drugs currently investigated for treatment of solid tumors
  publication-title: J. Physiol. Pharmacol.
– volume: 14
  start-page: 476
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b1235
  article-title: Folic Acid Modified Cationic gamma-Cyclodextrin-oligoethylenimine Star Polymer with Bioreducible Disulfide Linker for Efficient Targeted Gene Delivery
  publication-title: Biomacromolecules
  doi: 10.1021/bm301718f
– volume: 2
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1120
  article-title: Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer
  publication-title: Cancer Rep.-Us
– volume: 27
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1105
  article-title: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex (vol 22, 4, 2015)
  publication-title: J. Biomed. Sci.
  doi: 10.1186/s12929-020-00687-2
– volume: 339
  start-page: 819
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0035
  article-title: Multiplex Genome Engineering Using CRISPR/Cas Systems
  publication-title: Science
  doi: 10.1126/science.1231143
– volume: 12
  start-page: 278
  year: 2012
  ident: 10.1016/j.addr.2021.113891_b1020
  article-title: Antibody therapy of cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3236
– volume: I
  start-page: 540
  issue: 112
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0255
  article-title: Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids
  publication-title: Jnci-J. Natl. Cancer
  doi: 10.1093/jnci/djz196
– volume: 9
  start-page: 44045
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0945
  article-title: Tumor-targeted accumulation of ligand-installed polymeric micelles influenced by surface PEGylation crowdedness
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.7b16764
– volume: 11
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0335
  article-title: Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing
  publication-title: J. Ovarian Res.
  doi: 10.1186/s13048-018-0406-z
– volume: 24
  start-page: 1020
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0840
  article-title: Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
  publication-title: Genome Res.
  doi: 10.1101/gr.171264.113
– volume: 8
  start-page: 2274
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1175
  article-title: Tumor-targeting peptide functionalized PEG-PLA micelles for efficient drug delivery
  publication-title: Biomater Sci-Uk
  doi: 10.1039/C9BM02036E
– volume: 339
  start-page: 823
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0040
  article-title: RNA-Guided Human Genome Engineering via Cas9
  publication-title: Science
  doi: 10.1126/science.1232033
– volume: 12
  start-page: 16018
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1490
  article-title: Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.9b23084
– volume: 252
  start-page: 3582
  year: 1977
  ident: 10.1016/j.addr.2021.113891_b0915
  article-title: Effect of covalent attachment of polyethylene-glycol on immunogenicity and circulating life of bovine liver catalase
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(17)40292-4
– volume: 33
  start-page: 8759
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0300
  article-title: Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth
  publication-title: FASEB J.
  doi: 10.1096/fj.201802213RR
– volume: 13
  start-page: 82-+
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1140
  article-title: Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-017-0012-z
– volume: 37
  start-page: 410
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0160
  article-title: The application of the CRISPR-Cas9 genome editing machinery in food and agricultural science: Current status, future perspectives, and associated challenges
  publication-title: Biotechnol. Adv.
  doi: 10.1016/j.biotechadv.2019.02.006
– volume: 18
  start-page: 1507
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0665
  article-title: Porous inorganic drug delivery systems-a review
  publication-title: Aaps Pharmscitech
  doi: 10.1208/s12249-017-0740-2
– volume: 39
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0205
  article-title: Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
  publication-title: J Exp Clin Canc Res
  doi: 10.1186/s13046-020-01603-0
– volume: 56
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1265
  article-title: ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer
  publication-title: Chem. Commun.
  doi: 10.1039/D0CC06241C
– volume: 9
  start-page: 4487
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0585
  article-title: Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells
  publication-title: Acta Biomater.
  doi: 10.1016/j.actbio.2012.08.012
– volume: 13
  start-page: 187
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1285
  article-title: Super-resolution imaging of proton sponge-triggered rupture of endosomes and cytosolic release of small interfering RNA
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b05151
– volume: 96
  start-page: 13
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0015
  article-title: Advancements in CRISPR/Cas9 technology-Focusing on cancer therapeutics and beyond
  publication-title: Semin. Cell Dev. Biol.
  doi: 10.1016/j.semcdb.2019.05.026
– volume: 322
  start-page: 236
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0850
  article-title: Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.03.015
– volume: 147
  start-page: 68
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1135
  article-title: Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2017.09.015
– volume: 21
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0065
  article-title: Delivery of CRISPR/Cas9 for therapeutic genome editing
  publication-title: J. Gene Med.
  doi: 10.1002/jgm.3107
– volume: 324
  start-page: 194
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1370
  article-title: A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.04.052
– volume: 11
  start-page: 9
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b1255
  article-title: EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment
  publication-title: Nanomedicine-Uk
  doi: 10.2217/nnm.15.183
– volume: 116
  start-page: 255
  year: 2006
  ident: 10.1016/j.addr.2021.113891_b1320
  article-title: Cationic lipids, lipoplexes and intracellular delivery of genes
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2006.06.024
– volume: 57
  start-page: 1491
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1440
  article-title: Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201708689
– volume: 11
  start-page: 2352
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b1150
  article-title: Aptamers and their applications in nanomedicine
  publication-title: Small
  doi: 10.1002/smll.201403073
– volume: 330
  start-page: 502
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b0555
  article-title: Self-assembled polymeric vesicles: focus on polymersomes in cancer treatment
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.12.027
– volume: 9
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0385
  article-title: Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion
  publication-title: Sci. Rep.-Uk
– volume: 14
  start-page: 2817
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1445
  article-title: A genome-editing nanomachine constructed with a clustered regularly interspaced short palindromic repeats system and activated by near-infrared illumination
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b05276
– volume: 60
  start-page: 174
  year: 2005
  ident: 10.1016/j.addr.2021.113891_b0095
  article-title: Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements
  publication-title: J. Mol. Evol.
  doi: 10.1007/s00239-004-0046-3
– volume: 19
  start-page: 902
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0210
  article-title: RAS-targeted therapies: is the undruggable drugged? (vol 19, pg 533, 2020)
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-020-0089-1
– volume: 12
  start-page: 21001
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0825
  article-title: Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
  publication-title: Nanoscale
  doi: 10.1039/D0NR05452F
– volume: 258
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1475
  article-title: Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.120275
– volume: 10
  start-page: 412
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0050
  article-title: Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems
  publication-title: Clin. Transl. Med.
  doi: 10.1002/ctm2.34
– volume: 4
  start-page: 958
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0550
  article-title: Fabrication of dendrimer-releasing lipidic nanoassembly for cancer drug delivery
  publication-title: Biomater. Sci-Uk
  doi: 10.1039/C6BM00189K
– volume: 12
  start-page: 3117
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0515
  article-title: Current development of biodegradable polymeric materials for biomedical applications
  publication-title: Drug Des. Dev. Ther.
  doi: 10.2147/DDDT.S165440
– volume: 14
  start-page: 3389
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0700
  article-title: Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S198848
– volume: 11
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0360
  article-title: CRISPR-Cas9 knockdown and induced expression of CD133 reveal essential roles in melanoma invasion and metastasis
  publication-title: Cancers
  doi: 10.3390/cancers11101490
– volume: 33
  start-page: 73
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0640
  article-title: Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3081
– volume: 7
  start-page: 655
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0940
  article-title: Anti-PEG immunity: emergence, characteristics, and unaddressed questions
  publication-title: Wires Nanomed. Nanobi.
  doi: 10.1002/wnan.1339
– volume: 304
  start-page: 204
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0415
  article-title: Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2019.05.019
– volume: 11
  start-page: 313
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0695
  article-title: Mesoporous silica nanoparticles in drug delivery and biomedical applications
  publication-title: Nanomed.-Nanotechnol.
  doi: 10.1016/j.nano.2014.09.014
– volume: 7
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0745
  article-title: Redox-responsive tumor targeted dual-drug loaded biocompatible metal–organic frameworks nanoparticles for enhancing anticancer effects
  publication-title: BMC Mat.
– volume: 99
  start-page: 28
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0930
  article-title: PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
  publication-title: Adv. Drug Deliver. Rev.
  doi: 10.1016/j.addr.2015.09.012
– volume: 10
  start-page: 358
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1480
  article-title: Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity
  publication-title: Acta Pharmacol. Sin. B
  doi: 10.1016/j.apsb.2019.07.004
– volume: 57
  start-page: 7131
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1160
  article-title: Valency-controlled framework nucleic acid signal amplifiers
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201802701
– volume: 13
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0260
  article-title: CRISPR deletion of MIEN1 in breast cancer cells
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0204976
– volume: 31
  start-page: 309
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1355
  article-title: Human papillomavirus oncogene manipulation using clustered regularly interspersed short palindromic repeats/Cas9 delivered by pH-sensitive cationic liposomes
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2019.312
– volume: 5
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1430
  article-title: Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aav7199
– volume: 5
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0905
  article-title: A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aaw8922
– volume: 5
  start-page: 1877
  year: 2011
  ident: 10.1016/j.addr.2021.113891_b1295
  article-title: Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing
  publication-title: ACS Nano
  doi: 10.1021/nn102711d
– volume: 52
  start-page: 198-+
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0190
  article-title: ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-019-0554-0
– volume: 27
  start-page: 1
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1190
  article-title: RGD peptide-based non-viral gene delivery vectors targeting integrin alpha(v)beta(3) for cancer therapy
  publication-title: J. Drug Target.
  doi: 10.1080/1061186X.2018.1455841
– volume: 230
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0730
  article-title: Metal-organic frameworks for stimuli-responsive drug delivery
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2019.119619
– volume: 15
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1110
  article-title: Anti-EPCAM APTamer (Syl3c)-functionalized liposome for targeted delivery of doxorubicin. In vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma
  publication-title: Nanoscale Res. Lett.
  doi: 10.1186/s11671-020-03334-9
– volume: 11
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0975
  article-title: Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17029-3
– volume: 117
  start-page: 2395
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1450
  article-title: Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing
  publication-title: P. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1912220117
– volume: 6
  start-page: 1118
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b1005
  article-title: Nanoparticle-based targeted gene therapy for lung cancer
  publication-title: Am. J. Cancer Res.
– volume: 6
  start-page: 2174
  year: 2012
  ident: 10.1016/j.addr.2021.113891_b0715
  article-title: Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers
  publication-title: ACS Nano
  doi: 10.1021/nn204102q
– volume: 16
  start-page: 510
  year: 2009
  ident: 10.1016/j.addr.2021.113891_b1210
  article-title: Tissue-penetrating delivery of compounds and nanoparticles into tumors
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.10.013
– volume: 9
  start-page: 988
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0330
  article-title: Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening
  publication-title: Am. J. Cancer Res.
– volume: 392
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1055
  article-title: Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2020.112040
– volume: 169
  start-page: 5429
  year: 1987
  ident: 10.1016/j.addr.2021.113891_b0085
  article-title: Nucleotide-Sequence of the Iap Gene, Responsible for Alkaline-Phosphatase Isozyme Conversion in Escherichia-Coli, and Identification of the Gene-Product
  publication-title: J. Bacteriol.
  doi: 10.1128/jb.169.12.5429-5433.1987
– volume: 66
  start-page: 184
  year: 2002
  ident: 10.1016/j.addr.2021.113891_b1170
  article-title: Therapeutic cancer targeting peptides
  publication-title: Biopolymers
  doi: 10.1002/bip.10257
– volume: 11
  start-page: 226
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1100
  article-title: Multifunctional vector for delivery of genome editing plasmid targeting beta-catenin to remodulate cancer cell properties
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.8b17481
– volume: 111
  start-page: 76
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0400
  article-title: CRISPR/Cas9-mediated knockout of the PDEF gene inhibits migration and invasion of human gastric cancer AGS cells
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.12.048
– volume: 6
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0630
  article-title: Advances and challenges of liposome assisted drug delivery
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2015.00286
– volume: 117
  start-page: 513
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0230
  article-title: CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer
  publication-title: P. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1821893117
– volume: 103
  start-page: 598
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0590
  article-title: Nanostructured lipid carriers for site-specific drug delivery
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.04.055
– volume: 22
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0500
  article-title: Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy
  publication-title: Molecules
– volume: 321
  start-page: 654
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0885
  article-title: Hyperbranched poly(beta-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.02.045
– volume: 80
  start-page: 404
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1225
  article-title: Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems
  publication-title: Drug Develop. Res.
  doi: 10.1002/ddr.21545
– volume: 29
  start-page: 223
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1240
  article-title: In vivo ovarian cancer gene therapy using CRISPR-Cas9
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2017.209
– volume: 10
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0390
  article-title: Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-019-2093-0
– volume: 12
  start-page: 145
  year: 2011
  ident: 10.1016/j.addr.2021.113891_b0870
  article-title: Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin
  publication-title: Biomacromolecules
  doi: 10.1021/bm101080p
– volume: 18
  start-page: 175
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1455
  article-title: Delivery technologies for cancer immunotherapy
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-018-0006-z
– volume: 31
  start-page: 303
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0770
  article-title: Recent advances in molecular imaging with gold nanoparticles
  publication-title: Bioconjug. Chem.
  doi: 10.1021/acs.bioconjchem.9b00669
– volume: 57
  start-page: 10268
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0890
  article-title: Enhanced cytosolic delivery and release of CRISPR/Cas9 by black phosphorus nanosheets for genome editing
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201806941
– volume: 22
  start-page: 6959
  year: 2003
  ident: 10.1016/j.addr.2021.113891_b0225
  article-title: pRB(2)/p130 target genes in non-small lung cancer cells identified by microarray analysis
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206866
– volume: 43
  start-page: 1565
  year: 2002
  ident: 10.1016/j.addr.2021.113891_b0090
  article-title: Identification of genes that are associated with DNA repeats in prokaryotes
  publication-title: Mol. Microbiol.
  doi: 10.1046/j.1365-2958.2002.02839.x
– volume: 6
  start-page: 177
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b1205
  article-title: Dual receptor recognizing cell penetrating peptide for selective targeting efficient intratumoral diffusion and synthesized anti-glioma therapy
  publication-title: Theranostics
  doi: 10.7150/thno.13532
– volume: 96
  start-page: 1314
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0355
  article-title: CRISPR/Cas9-mediated knockout of SIRT6 imparts remarkable antiproliferative response in human melanoma cellsin vitroandin vivo
  publication-title: Photochem. Photobiol.
  doi: 10.1111/php.13305
– volume: 371
  start-page: 1
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1025
  article-title: Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2018.08.009
– volume: 321
  start-page: 285
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0875
  article-title: Synthesis and functionalization of hyperbranched polymers for targeted drug delivery
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.02.019
– volume: 84
  start-page: 7413
  year: 1987
  ident: 10.1016/j.addr.2021.113891_b0635
  article-title: Lipofection - a highly efficient, lipid-mediated DNA-transfection procedure
  publication-title: P. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.84.21.7413
– volume: 190
  start-page: 1390
  year: 2008
  ident: 10.1016/j.addr.2021.113891_b0115
  article-title: Phage response to CRISPR-Encoded resistance in Streptococcus thermophilus
  publication-title: J. Bacteriol.
  doi: 10.1128/JB.01412-07
– volume: 106
  start-page: 148
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b1045
  article-title: Extracellular vesicles for drug delivery
  publication-title: Adv. Drug Deliver. Rev.
  doi: 10.1016/j.addr.2016.02.006
– volume: 10
  start-page: 1688
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0920
  article-title: Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating
  publication-title: Drug Deliv. Transl. Re.
  doi: 10.1007/s13346-020-00816-2
– volume: 9
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1090
  article-title: Aptamer-based targeted delivery of a g-quadruplex ligand in cervical cancer cells
  publication-title: Sci. Rep.-Uk
– volume: 140
  start-page: 143
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1300
  article-title: Endosomal escape and delivery of CRISPR/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.7b11754
– volume: 7
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1335
  article-title: Appropriate delivery of the CRISPR/Cas9 system through the nonlysosomal route: application for therapeutic gene editing
  publication-title: Adv. Sci.
  doi: 10.1002/advs.201903381
– volume: 25
  start-page: 1837
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1345
  article-title: Stimuli responsive nanoparticles for controlled anti-cancer drug release
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867325666180111095913
– volume: 3
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0145
  article-title: Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
  publication-title: Elife
  doi: 10.7554/eLife.04766
– volume: 5
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0965
  article-title: HPV Oncogene Manipulation Using Nonvirally Delivered CRISPR/Cas9 or Natronobacterium gregoryi Argonaute
  publication-title: Adv. Sci.
  doi: 10.1002/advs.201700540
– volume: 353
  start-page: 399
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b1485
  article-title: Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
  publication-title: Science
  doi: 10.1126/science.aae0477
– volume: 6
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0845
  article-title: CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abc9450
– volume: 53
  start-page: 12320
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b1220
  article-title: Engineered nanoparticles for drug delivery in cancer therapy
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201403036
– volume: 14
  start-page: 601
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b1415
  article-title: Chain-shattering Pt(IV)-backboned polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic cancer therapy
  publication-title: Nano Res.
  doi: 10.1007/s12274-020-3066-4
– volume: 12
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0625
  article-title: Continuous-flow production of liposomes with a millireactor under varying fluidic conditions
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12111001
– volume: 26
  start-page: 2443
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0860
  article-title: Nanoparticles based on poly (beta-Amino Ester) and HPV16-targeting CRISPR/shRNA as potential drugs for HPV16-related cervical malignancy
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2018.07.019
– year: 2020
  ident: 10.1016/j.addr.2021.113891_b1030
  article-title: Recent advances in HER2-targeted delivery for cancer therapy
  publication-title: Drug Discov. Today
– volume: 14
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1360
  article-title: Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids
  publication-title: Small
  doi: 10.1002/smll.201803061
– volume: 90
  start-page: 2331
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0545
  article-title: Perspectives of dendrimer-based nanoparticles in cancer therapy
  publication-title: An. Acad. Bras. Cienc
  doi: 10.1590/0001-3765201820170387
– volume: 11
  start-page: 923
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0760
  article-title: Surface chemistry of gold nanoparticles for health-related applications
  publication-title: Chem. Sci.
  doi: 10.1039/C9SC06497D
– volume: 13
  start-page: 288
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0595
  article-title: Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages
  publication-title: Res. Pharm. Sci.
  doi: 10.4103/1735-5362.235156
– volume: 18
  start-page: 154
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0720
  article-title: Metal-organic frameworks (MOFs) as functional supramolecular architectures for anion recognition and sensing
  publication-title: Chem. Rec.
  doi: 10.1002/tcr.201700033
– volume: 171
  start-page: 207
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0800
  article-title: Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2018.04.031
– volume: 9
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0955
  article-title: Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
  publication-title: NPG Asia Mater.
  doi: 10.1038/am.2017.185
– volume: 168
  start-page: 3
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b0805
  article-title: Rational designs of in vivo CRISPR-Cas delivery systems
  publication-title: Adv. Drug Deliver. Rev.
  doi: 10.1016/j.addr.2019.11.005
– volume: 10
  start-page: 161
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b1035
  article-title: Nanobody-based cancer therapy of solid tumors
  publication-title: Nanomedicine-Uk
  doi: 10.2217/nnm.14.178
– volume: 16
  start-page: 497
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0830
  article-title: Deep eutectic solvents comprising active pharmaceutical ingredients in the development of drug delivery systems
  publication-title: Expert. Opin. Drug Deliv.
  doi: 10.1080/17425247.2019.1604680
– volume: 27
  start-page: 2091
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0950
  article-title: Systemic delivery of CRISPR/Cas9 targeting HPV oncogenes is effective at eliminating established tumors
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2019.08.012
– volume: 1190
  start-page: 197
  year: 1994
  ident: 10.1016/j.addr.2021.113891_b0660
  article-title: Transmembrane ammonium-sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases
  publication-title: Bba-Biomembranes
– volume: 5
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0740
  article-title: Aptamer-mediated up-conversion core/MOF shell nanocomposites for targeted drug delivery and cell imaging
  publication-title: Sci. Rep.-Uk
– volume: 185
  start-page: 22
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0645
  article-title: Nano-niosomes as nanoscale drug delivery systems: an illustrated review
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2014.04.015
– volume: 48
  start-page: 8870
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1155
  article-title: Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkaa683
– volume: 10
  start-page: 1171
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0560
  article-title: Emerging era of “somes”: polymersomes as versatile drug delivery carrier for cancer diagnostics and therapy
  publication-title: Drug Deliv. Transl. Re
  doi: 10.1007/s13346-020-00789-2
– volume: 35
  start-page: 4835
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b1200
  article-title: Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2014.02.031
– volume: 3
  start-page: 347
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0755
  article-title: Doxorubicin-conjugated pH-responsive gold nanorods for combined photothermal therapy and chemotherapy of cancer
  publication-title: Bioact. Mater.
– volume: 9
  start-page: 3740
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0530
  article-title: Complete regression of xenograft tumors upon targeted delivery of paclitaxel via Pi-Pi stacking stabilized polymeric micelles
  publication-title: ACS Nano
  doi: 10.1021/acsnano.5b00929
– volume: 7
  start-page: 500
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0815
  article-title: Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging
  publication-title: ACS Nano
  doi: 10.1021/nn3046055
– volume: 49
  start-page: 2273
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0910
  article-title: Influence of nanomedicine mechanical properties on tumor targeting delivery
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/C9CS00575G
– year: 2021
  ident: 10.1016/j.addr.2021.113891_b0810
  article-title: Obstacles and opportunities in a forward vision for cancer nanomedicine
  publication-title: Nat. Mater.
  doi: 10.1038/s41563-021-01047-7
– volume: 32
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0855
  article-title: Aptamer/peptide-functionalized genome-editing system for effective immune restoration through reversal of PD-L1-mediated cancer immunosuppression
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202000208
– volume: 21
  start-page: 87
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0650
  article-title: Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations
  publication-title: Drug Deliv.
  doi: 10.3109/10717544.2013.838077
– volume: 26
  start-page: 290
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0195
  article-title: Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1351
– volume: 27
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0775
  article-title: Optimization of anti-cancer drugs and a targeting molecule on multifunctional gold nanoparticles
  publication-title: Nanotechnology
  doi: 10.1088/0957-4484/27/18/185704
– volume: 19
  start-page: 486
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0985
  article-title: A nanoparticle’s pathway into tumours
  publication-title: Nat. Mater.
  doi: 10.1038/s41563-020-0669-9
– volume: 31
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1350
  article-title: Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201900795
– volume: 8
  start-page: 94666
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0325
  article-title: Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.21863
– volume: 326
  start-page: 455
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1065
  article-title: Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2020.07.033
– volume: 19
  start-page: 495
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0170
  article-title: Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0179-8
– volume: 10
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0340
  article-title: CRISPR/Cas9-mediated OC-2 editing inhibits the tumor growth and angiogenesis of ovarian cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.01529
– volume: 6
  start-page: 3975
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0925
  article-title: Effect of poly(ethylene glycol) (PEG) surface density on the fate and antitumor efficacy of redox-sensitive hybrid nanoparticles
  publication-title: ACS Biomater. Sci. Eng.
  doi: 10.1021/acsbiomaterials.0c00516
– volume: 17
  start-page: 373
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0580
  article-title: Hydrogel-based controlled drug delivery for cancer treatment: a review
  publication-title: Mol. Pharmaceut.
– volume: 266
  start-page: 8
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1060
  article-title: Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2017.09.013
– volume: 3
  start-page: 217
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b0125
  article-title: Blossom of CRISPR technologies and applications in disease treatment
  publication-title: Syn. Syst. Biotechno.
  doi: 10.1016/j.synbio.2018.10.003
– volume: 58
  start-page: 924
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1245
  article-title: Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review
  publication-title: Crit. Rev. Food Sci.
  doi: 10.1080/10408398.2016.1231168
– volume: 19
  start-page: 1840
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1420
  article-title: Photoresponsive drug/gene delivery systems
  publication-title: Biomacromolecules
  doi: 10.1021/acs.biomac.8b00422
– volume: 12
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0735
  article-title: Metal-organic framework nanocarriers for drug delivery in biomedical applications
  publication-title: Nano-Micro Lett.
  doi: 10.1007/s40820-020-00423-3
– volume: 240
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0675
  article-title: Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.119791
– volume: 10
  start-page: 1440
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0305
  article-title: CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.26677
– year: 2021
  ident: 10.1016/j.addr.2021.113891_b0765
  article-title: Intraoperative assessment and photothermal ablation of the tumor margins using gold nanoparticles
  publication-title: Adv. Sci.
  doi: 10.1002/advs.202002788
– volume: 11
  start-page: 46585
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1390
  article-title: Cell-selective messenger RNA delivery and CRISPR/Cas9 genome editing by modulating the interface of phenylboronic acid-derived lipid nanoparticles and cellular surface sialic acid
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.9b17749
– volume: 181
  start-page: 151
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1010
  article-title: Targeting strategies for tissue-specific drug delivery
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.001
– volume: 2016
  start-page: 197
  year: 1866
  ident: 10.1016/j.addr.2021.113891_b0010
  article-title: CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
  publication-title: Bba-Rev. Cancer
– volume: 33
  start-page: 18
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0525
  article-title: Polymeric micelles: recent advancements in the delivery of anticancer drugs
  publication-title: Pharm. Res.-Dordr.
  doi: 10.1007/s11095-015-1784-1
– volume: 109
  start-page: 12426
  year: 2012
  ident: 10.1016/j.addr.2021.113891_b1250
  article-title: Laminin receptor specific therapeutic gold nanoparticles ((AuNP)-Au-198-EGCg) show efficacy in treating prostate cancer
  publication-title: P. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1121174109
– volume: 11
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0180
  article-title: CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.02062
– volume: 5
  start-page: 209
  year: 2011
  ident: 10.1016/j.addr.2021.113891_b0475
  article-title: Uniformity of drug payload and its effect on stability of solid lipid nanoparticles containing an ester prodrug
  publication-title: ACS Nano
  doi: 10.1021/nn102357y
– volume: 26
  start-page: 782-+
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0200
  article-title: Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2020.04.003
– volume: 341
  start-page: 833
  year: 2013
  ident: 10.1016/j.addr.2021.113891_b0025
  article-title: The CRISPR Craze
  publication-title: Science
  doi: 10.1126/science.341.6148.833
– volume: 13
  start-page: 3921
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1015
  article-title: Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S165210
– volume: 19
  start-page: 1491
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0495
  article-title: Peptides as potential anticancer agents
  publication-title: Curr. Top. Med. Chem.
  doi: 10.2174/1568026619666190125161517
– volume: 54
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b0380
  article-title: The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids
  publication-title: Cell Proliferat
  doi: 10.1111/cpr.12965
– volume: 8
  start-page: 9375
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1130
  article-title: Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14072
– volume: 67
  start-page: 657-+
  year: 2003
  ident: 10.1016/j.addr.2021.113891_b0005
  article-title: RNA interference: Biology, mechanism, and applications
  publication-title: Microbiol. Mol. Biol. R
  doi: 10.1128/MMBR.67.4.657-685.2003
– volume: 8
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1115
  article-title: New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2018.00653
– volume: 55
  start-page: 106
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0045
  article-title: CRISPR/Cas9 for cancer research and therapy
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2018.04.001
– volume: 11
  start-page: 34717
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1365
  article-title: Gold nanocluster-mediated efficient delivery of Cas9 protein through pH-induced assembly-disassembly for inactivation of virus oncogenes
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.9b12335
– volume: 32
  start-page: 1909
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b1425
  article-title: Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods
  publication-title: Laser Med. Sci.
  doi: 10.1007/s10103-017-2317-4
– volume: 1
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0995
  article-title: Analysis of nanoparticle delivery to tumours
  publication-title: Nat. Rev. Mater.
  doi: 10.1038/natrevmats.2016.14
– volume: 26
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0185
  article-title: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
  publication-title: Nat. Med.
– volume: 54
  start-page: 12029
  year: 2015
  ident: 10.1016/j.addr.2021.113891_b0900
  article-title: Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201506030
– volume: 134
  start-page: 65
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1070
  article-title: Aptamer-based targeted therapy
  publication-title: Adv Drug Deliver Rev
  doi: 10.1016/j.addr.2018.08.005
– volume: 40
  start-page: 909
  year: 2021
  ident: 10.1016/j.addr.2021.113891_b0245
  article-title: NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration
  publication-title: Oncogene
  doi: 10.1038/s41388-020-01570-y
– volume: 147
  start-page: 2902
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0370
  article-title: The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.33252
– volume: 11
  start-page: 11136
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0395
  article-title: Ninjurin2 overexpression promotes glioma cell growth
  publication-title: Aging-Us
  doi: 10.18632/aging.102515
– volume: 7
  start-page: 83502
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0435
  article-title: Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13148
– volume: 568
  start-page: 511-+
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0465
  article-title: Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
  publication-title: Nature
  doi: 10.1038/s41586-019-1103-9
– volume: 315
  start-page: 1709
  year: 2007
  ident: 10.1016/j.addr.2021.113891_b0105
  article-title: CRISPR provides acquired resistance against viruses in prokaryotes
  publication-title: Science
  doi: 10.1126/science.1138140
– volume: 140
  start-page: 6596
  year: 2018
  ident: 10.1016/j.addr.2021.113891_b1275
  article-title: Receptor-mediated delivery of CRISPR-Cas9 endonuclease for cell-type-specific gene editing
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.8b01551
– volume: 12
  start-page: 2437
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b0075
  article-title: Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect
  publication-title: Nano Res.
  doi: 10.1007/s12274-019-2465-x
– volume: 19
  start-page: 7765
  year: 2009
  ident: 10.1016/j.addr.2021.113891_b0710
  article-title: An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates
  publication-title: J. Mater. Chem.
  doi: 10.1039/b907978e
– volume: 33
  start-page: 334
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0365
  article-title: A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma
  publication-title: Pigm. Cell Melanoma R
  doi: 10.1111/pcmr.12825
– volume: 11
  start-page: 133
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0835
  article-title: Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines
  publication-title: Nano Today
  doi: 10.1016/j.nantod.2016.04.008
– volume: 14
  start-page: 8012
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b1290
  article-title: Lysosomal proton buffering of poly(ethylenimine) measured in situ by fluorescent pH-sensor microcapsules
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b10219
– volume: 8
  start-page: 22442
  year: 2016
  ident: 10.1016/j.addr.2021.113891_b0795
  article-title: pH-sensitive ZnO quantum dots-doxorubicin nanoparticles for lung cancer targeted drug delivery
  publication-title: Acs Appl Mater Inter
  doi: 10.1021/acsami.6b04933
– volume: 266
  start-page: 17
  year: 2017
  ident: 10.1016/j.addr.2021.113891_b0060
  article-title: Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2017.09.012
– volume: 151
  start-page: 2551
  year: 2005
  ident: 10.1016/j.addr.2021.113891_b0100
  article-title: Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin
  publication-title: Microbiol-Sgm
  doi: 10.1099/mic.0.28048-0
– volume: 45
  start-page: 2287
  year: 2007
  ident: 10.1016/j.addr.2021.113891_b0880
  article-title: Dendritic polyamine architectures with lipophilic shells as nanocompartments for polar guest molecules: a comparative study of their transport behavior
  publication-title: J. Polym. Sci. Pol. Chem.
  doi: 10.1002/pola.21996
– volume: 17
  start-page: 300
  year: 2020
  ident: 10.1016/j.addr.2021.113891_b0220
  article-title: Immunotherapeutic approaches for small-cell lung cancer
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-019-0316-z
– volume: 9
  start-page: 535
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b0670
  article-title: Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications
  publication-title: Nanomedicine-Uk
  doi: 10.2217/nnm.13.223
– volume: 448
  start-page: 144
  year: 2019
  ident: 10.1016/j.addr.2021.113891_b1085
  article-title: Aptamer-functionalized liposomes for targeted cancer therapy
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.01.045
– volume: 9
  start-page: 907
  year: 2014
  ident: 10.1016/j.addr.2021.113891_b1260
  article-title: Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/nnano.2014.208
SSID ssj0012760
Score 2.6825204
SecondaryResourceType review_article
Snippet [Display omitted] CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing...
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 113891
SubjectTerms Animals
Cancer treatment
Clinic application
CRISPR-Cas Systems
CRISPR/Cas9
Delivery vectors
Gene Editing
Humans
Nanotechnology
Nanotechnology - methods
Neoplasms - genetics
Neoplasms - therapy
Title Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
URI https://dx.doi.org/10.1016/j.addr.2021.113891
https://www.ncbi.nlm.nih.gov/pubmed/34324887
https://www.proquest.com/docview/2557229042
Volume 176
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1872-8294
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0012760
  issn: 0169-409X
  databaseCode: AIEXJ
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLXYBmgvCMZX-ZiMhPayZUviJLYfKzTEEBrVKCg8RXbsjE4jqdpmWv8913HiVLBO8MBL1MSOU-XcHF_bx_ci9Fb5Mk9EDsMSIkMv4r70REEJnHLiS0UlaQKYfvtET09ZmvJRK2ueN-kEaFmy62s-_a9QwzUA22yd_Qe4XaNwAX4D6HAE2OH4V8ADX1YLN2HumW5K7St9aQQYVn1xdvJldGYC44o5b2SGuYF-1ovOVz3WYScSULP6vG-njWLa4ZXWBqt0Iqpl7TQ-k7pd0G97x2be3nLL96o8_1FPHN1XkysT48AUfW6esDobEQZObgWdiWVQRoFiQ5u52FEsXSXJoFkcvZG_7VTCxSGwrgnWGgaHf1aG1z392YBnNsUCAdG-L3MKw65oA22FNObAd1vDk-P0o1thCmnit5uorN7v90duo_tdI-t8lnVjksY3GT9ED9pBBR5aY3iE7uhyB92zaUaXO2hvZOOTLw_wuN9uNz_Ae3jURy5fPkbDm2wHd5jjqsDWdo6M5WCwHGwtBzvLeYK-vj8ev_vgtTk2vBx8tcBLOFFSRYFPc2DyOKAyYhGTQjKlY0Z0ToWUhBQsZoIkRPki4AUHt1jHJBGqIE_RZlmV-jnCiic81jpKGGdGbCVoCDV0XLA8iliuBijo3mKWtwHoTR6Uy6xTGl5kBoTMgJBZEAZo390zteFXbq0dd-BkrQNpHcMM7OvW-950SGbArmbJTJS6qucZDLipyYgQhQP0zELs_kdnHS_WlrxE2_038gptLma1fo3u5leLyXy2izZoynZbu_wFq3-c1w
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanotechnology-based+delivery+of+CRISPR%2FCas9+for+cancer+treatment&rft.jtitle=Advanced+drug+delivery+reviews&rft.au=Xu%2C+Xiaoyu&rft.au=Liu%2C+Chang&rft.au=Wang%2C+Yonghui&rft.au=Koivisto%2C+Oliver&rft.date=2021-09-01&rft.eissn=1872-8294&rft.volume=176&rft.spage=113891&rft_id=info:doi/10.1016%2Fj.addr.2021.113891&rft_id=info%3Apmid%2F34324887&rft.externalDocID=34324887
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0169-409X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0169-409X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0169-409X&client=summon